SUPPLEMENT

FY2020 — Results booklet

FY2020PDF · 56 pages2.7 MB
DISCOVERY
AUDITED RESULTS
2020
FOR THE YEAR ENDED 30 JUNE

-- 1 of 56 --

Normalised profit from operations
(R million)
2016
2017
2018
2019
2020
 
6 069
7 747
8 266
7 048
6 407
Gross inflows under management
(R million)
2016
2017
2018
2019
2020
 
154 833
139 062
125 554
115 061
104 409
Embedded value
(R million)
2016
2017
2018
2019
2020
 
70 834	
71 217
65 624
57 294
53 080
Core new business API
(R million)
2016
2017
2018
2019
2020
 
19 173
18 329
16 137
14 660
13 303

-- 2 of 56 --

1
FINANCIAL PERFORMANCE
Performance over the period was framed by the following key issues:
Operating performance was resilient
For the full year ended 30 June 2020, core new business was up 5% to R19 173 million, normalised operating profit was up 9% to
R8 409 million (before providing for future COVID-19-related impacts, decreasing by 22% after the provision to R6 069 million) and
normalised headline earnings decreased by 26% to R3 747 million. Normalised headline earnings per share (diluted) decreased by
27% to 566.7 cents and headline earnings per share (diluted) decreased by 94% to 44.7 cents.
The following table summarises the position:
Metrics
% change
over prior year
Group normalised profit from operations (before allowing for COVID-19 provision) 	9%
Group normalised profit from operations (after allowing for COVID-19 provision) 	(22%)
Group normalised headline earnings 	(26%)
Headline earnings (after economic assumption changes due to long-term interest rates) 	(94%)
Per-business performance was also resilient as outlined below:
Business
Operating profit before
reserving for
future COVID-19 impacts 	New business Strategic observation
Discovery Health 	+5% 	-9%
Showed continued operational excellence and provided
significant support to members and society
Discovery Life
+25%
(-8% after COVID-19 provision) 	-1%
Rebounded after a challenging FY19 with positive
operational experience variances and cash generation
Discovery Invest 	-14% 	+2% Continued strong asset gathering amid a weak market
Discovery Insure 	+59% 	+5%
Continued scaling while demonstrating high quality
of business
Discovery Bank 	+296% operating loss increase
Successfully completed client migrations, fully deposit
funded; rapid learnings to improve user experience and
value proposition
VitalityHealth
+104%
(+9% after COVID-19 reserve) 	-8%
Operational excellence with a continued focus on quality
of business and relevance resulting in excellent retention
VitalityLife
-49%
(-147% after COVID-19 provision) 	-3%
Executed on its turnaround plan; set up for future
recovery
Vitality Group 	+91% 	+23%
Resilient revenue and strong operational leverage driving
growth; increasing relevance with partners adopting
Shared-Value model
Ping An Health 	+72% 	+42%
Exceptional growth; continuing to invest for
long-term opportunity
Commentary
The full-year period to 30 June 2020 was uniquely complex, with the COVID-19 pandemic creating
considerable economic uncertainty, market volatility and societal need, against an already
challenging economic backdrop. Discovery’s response was focused on three areas: protecting its
people, protecting and supporting its clients, and supporting country efforts in South Africa –
underpinned by a disciplined strategy to maintain Group financial strength and resilience.

-- 3 of 56 --

2 Discovery Audited results for the year ended 30 June 2020
COMMENTARY continued
Actuarial dynamics also performed well and demonstrated
particular resilience during the final quarter of the year. Over
the period, South Africa (SA) and the United Kingdom (UK)
experienced severe lockdowns, however lapse experience was
contained within Discovery’s actuarial assumptions for all
businesses, except Discovery Invest. Claims experience was
also better than assumption for all operations, except
VitalityLife, where the effects of the pandemic emerged
sooner. New business was curtailed during the various
lockdown periods, but the impact was mitigated by increased
digital enablement. This was particularly evident in Ping An
Health, which delivered significant growth through its digital
channel during China’s lockdown period.
A reserve of R3.4 billion was
created to cater for all future
COVID-19 impacts
The Group provided R3.4 billion for future COVID-19-related
impacts on claims and lapses, so the expected effects to
December 2021 are fully recognised and reserved for in the
2020 reporting year. This resulted in a R2.3 billion profit
impact, net of discretionary margins. Discovery’s own data and
insights have been overlaid onto global and local data to build
sophisticated models to consider three scenarios, with the
provisions established in the medium scenario, as a prudent
best estimate.
Interest rate movements had a
R4.8 billion pre-tax effect on
headline earnings
In terms of long-term interest rates, the significant movements
in positive real rates of return in SA and negative real rates of
return in the UK has a significant effect on policy values and
headline earnings, but none on cash flows, solvency or capital
in SA; and since the implementation of the hedge strategy –
little impact in the UK. The impact in the period was R3.6 billion
for Discovery Life and £60.5 million net of the valuation of
the hedge for VitalityLife, with no bearing on operating
performance. These have been normalised out of the Group’s
financial result.
The growth model performed
well, with substantial, planned
investment of R2.2 billion into
new businesses
In terms of the growth model, the businesses delivered a
resilient operating performance. Established businesses saw
an increase in operating profit of 15% before the COVID-19
provisioning at R9.9 billion (reducing to -13% after), with
pleasing new business growth. The emerging businesses
saw remarkable growth, delivering a combined profit of
R736 million – 74% higher than the prior period. Investment in
new businesses was at 26% of normalised operating earnings
(before the COVID-19 reserve), compared with 17% in the
previous financial year, with these initiatives demonstrating
compelling progress. Discovery Bank completed all migrations
onto its platform and was able to fully fund its credit book with
deposits; Vitality Invest doubled total funds under management
over the recent six-month period; Umbrella Funds has a
strong pipeline of committed funds; and the V1 platform
continued to expand into new markets.
The Group focused on capital
strength and liquidity
Regarding capital and cash management, the capital metrics
remained above target for all businesses, with internal liquidity
bolstered for key businesses. The Group’s Financial Leverage
Ratio was at 25.1%1 and the South African liquidity2 of
R1.9 billion remains above target. These metrics remain
resilient into future periods under the low/stressed COVID-19
scenario.
The return on embedded value was 2% for the year (5%
excluding economic impacts and forex gains), also affected by
the COVID-19 provision and other non-economic methodology
and assumption changes predominantly in Discovery Life and
VitalityLife.
1 Excludes capitalised lease liabilities under the newly adopted IFRS16 and bank borrowings related to normal course lending and borrowing
activities of Discovery Bank
2 South African cash and undrawn committed facilities

-- 4 of 56 --

3
HEIGHTENED RELEVANCE OF THE
VITALITY SHARED-VALUE BUSINESS
MODEL; CONTINUED INVESTMENT
IN DISCOVERY’S STRATEGIC
FOUNDATION
Discovery is well positioned to respond to the pandemic, given
its Shared-Value business model is premised on, and
responsive to, three trends being accelerated as a result of
COVID-19. This includes firstly, the behavioural nature of risk,
given the emerging importance of healthy living in determining
not only non-communicable disease risk but communicable
disease risk as well. Secondly, technology is emerging as a key
enabler, given the rush to an online world. Thirdly, there is
heightened demand for purpose-based business models,
given the need to find profitable solutions to society’s
challenges.
The above resulted in continued investment in the model,
strengthened by its ongoing recognition and adoption, and by
the data supporting its efficacy across industries. This
manifested in developments across the business model’s
value chain (attraction, conversion, pricing, behaviour change,
retention) including the following: development of a Resilience
Index, linking Vitality engagement to the risk of COVID-19
complications; the continued roll-out of Discovery’s integrated
capabilities to the global market, courtesy of its V1 platform;
the evolution of Discovery Health’s leading digital healthcare
platform; and AI Quote, an artificial intelligence quoting tool
offering personalised advice to prospective clients.
By leveraging established structures for sharing value
combined with sophisticated data tracking and analytics
capabilities, the Group was able to rapidly respond to client
needs and provide concessions. Over R750 million was offered
to individuals and employers enabling them to continue
receiving cover; and a total of R12 billion was generated
in the form of shared value for clients in FY20, spanning
premium discounts, cash backs, boosts and value added by
managing care.
BUSINESS-SPECIFIC PERFORMANCE
Discovery’s Ambition 2023 remains the strategic focus for the
medium term, with the goal of being a leading financial
services organisation globally, positively influencing 100 million
lives – with 10 million directly insured – and being a powerful
force for social good.
Key to achieving this is Discovery’s execution of market-
specific strategies, namely:
i. 	South Africa: a disruptive composite model, with market-
leading businesses and a successful entry into banking
ii. United Kingdom: a differentiated offering through a
composite Vitality Shared-Value business model
iii. Ping An Health: the leading health insurer in China with
over 50 million clients
iv. Vitality Group: a sophisticated global behaviour-change
platform linked to financial services

-- 5 of 56 --

4 Discovery Audited results for the year ended 30 June 2020
COMMENTARY continued
South Africa
The SA business demonstrated resilience amid the
difficult economic and operating environment.
Excluding new initiatives, combined new business
reduced by 4% to R12 278 million and operating
profit increased by 11% to R8 302 million before the
COVID-19 provision (reducing by 3% after). Cash
generation across the established SA businesses was
also strong at R5.4 billion and all entities have shown
increases in their capital positions.
The SA business responded rapidly in addressing the impact of
COVID-19 on both employees and clients, and demonstrated
operational, financial and business resilience over the period.
Several benefits of the composite model were leveraged to
provide support to customers. For example, cross-company
data helped to identify more than 35 000 high-risk members
who were proactively assisted to help manage their risk.
In addition, the relevance of the Vitality programme, a
cornerstone of the composite strategy, was enhanced through
the launch of several ‘at home’ benefits to drive member
growth and engagement. Correlations of behaviours revealed
that Vitality members with deeper integration maintained
higher engagement and goal completion.
There is significant opportunity to leverage Discovery’s Shared-
Value composite model to increase product penetration and
stickiness across Discovery’s high-quality customer base, with
Discovery Bank serving as the monetisation and payment
mechanism for the composite. Discovery expects technology
efficiencies and increased digital enablement to further
improve distribution capability, supporting deeper penetration
in its distribution channel and target market.
Discovery Health
Financial resilience
Discovery Health (DH) delivered a strong financial
performance despite the challenging period.
Normalised operating profit increased by 5% to
R3 190 million and total revenue grew 8% to
R8 373 million, with non-scheme revenue showing
accelerated growth of 23%. Total new business API
decreased by 9% to R6 101 million, affected by the
difficult economic environment and contraction in
employment, which translated into a marked year-
on-year decline of new business from newly
recruited employees joining existing employee
groups. The business continued to tightly control
management expenses, resulting in a 1.4% decrease
in operational expenses on a per-member basis
(excl. non-recurring COVID-19-related costs). DH
made progress in growing non-scheme retail
products through Discovery Primary Care, Gap Cover
and Healthy Company, which now account for
c.184 000 lives under DH administration and
contribute 3% to overall DH revenue.
Discovery Health Medical Scheme (DHMS) continued
to perform excellently, growing open medical
scheme market share to 56.8% in a declining market.
The operating result and solvency were higher than
expected as a result of the reduction in health
system utilisation during lockdown, which included
a 27.5% reduction in hospital admissions at the end
of August 2020. Notwithstanding this higher-than-
anticipated surplus, the contribution increase for
2021 must be sufficient to sustain a small operating
surplus and keep up with the utilisation catch-up, in
order to mitigate the risk of a high contribution
increase for 2022, by which time utilisation is
expected to have recovered fully from the depressed
levels due to COVID-19. The surplus built up is thus
projected to reverse in 2021 following catch-up
of normal non-COVID-19 healthcare utilisation,
deferred hospital admissions, a likely muted annual
contribution increase and the full year’s impact of
COVID-19 costs.

-- 6 of 56 --

5
Business Relevance
DH’s response to COVID-19 translated into multiple initiatives
aimed at assisting employees, members, the healthcare
system and society. DH’s integration into the healthcare
system and population-level data insights allowed it to protect
high-risk members of administered medical schemes with
proactive care and interventions. This included administering
more than 28 000 flu vaccinations to at-risk members to
ensure the health system was not overwhelmed by dual
infections and providing care at home for over 7 500 members
including remote monitoring of oxygen saturation. This
resulted in materially lower morbidity (27% lower hospital
admissions) and mortality (38% lower case fatality rate) in
these engaged cohorts than in similar control groups.
COVID-19 has accelerated the transition towards digital
healthcare, with regulatory changes supporting doctor
engagement on digital platforms. Discovery also extended
access of the DrConnect (virtual consultation) platform to all
South Africans, growing platform usage 19x (June year-on-
year) with a total of 18 308 telemedicine consultations over the
period. DH is evolving this service to deliver user-friendly
digital tools on a powerful digital health platform, to be
announced at the launch in late September 2020.
DH’s continued investment in digital technologies and
automation also enabled the business to extract operational
efficiencies, drive down healthcare costs and improve member
experience. The DH and DHMS Critical 25 programme, which
involved an investment of R80 million directed at automation
to reduce call and email volumes and to increase DHMS claims
management, is on track to realise a three-year cumulative
ROI of 6.4x by September 2020.
COVID-19 has also created opportunities for public-private
partnerships, with DH supporting the National Department of
Health in SA to launch a digital COVID-19 contact tracing
solution. DH will continue to engage with relevant stakeholders
to participate in the creation of a sustainable public and
private healthcare system.
Discovery Life
Financial Resilience
Discovery Life (DL) delivered a strong operating
performance despite the challenging environment.
Claims experience improved significantly compared
to FY19, supporting a 25% increase in normalised
operational earnings, pre-COVID-19 provisioning, to
R4 029 million (down 8% to R2 971 million after
the provision). New business decreased by 1% to
R2 286 million, with strong Automatic Contribution
Increases (+10%) and the total in-force premium up
by 7%. DL delivered positive operational experience
variances overall and on all key metrics other than
policy alterations, given the allowance and take-up
of COVID-19 premium relief options and other buy
downs during the lockdown period. The business’s
financial position remains robust with strong cash
flow generation of R2.4 billion, increasing the
tangible free assets to R4.1 billion (both including
Discovery Invest) to provide high levels of liquidity.
The solvency cover ratio also increased to 182% from
159% at FY19.
Business Relevance
A key focus over the period was to support new business
activity through digital and remote processes. Medical
underwriting became available as the lockdown was eased.
While the travelling Smart Service nurses were unavailable
during the initial lockdown period, they are now being
deployed into “mini-labs”, which are situated in Discovery
franchises across the country – supplemented by travelling
nurses where appropriate.
DL leveraged the Vitality Shared-Value business model to
implement four COVID-19 premium relief options to support
clients, which ensured c.R34 billion of cover was kept in force.
The business also assisted clients and their families by tracking
and managing COVID-19 cases and utilising health data to
proactively reach out to those eligible for claims, as well as
distributing 1143 pulse oximeters to high-risk clients.

-- 7 of 56 --

6 Discovery Audited results for the year ended 30 June 2020
COMMENTARY continued
Discovery Invest
Financial Resilience
Discovery Invest’s performance reflected the
challenges of COVID-19 and volatile financial
markets. 	Total 	Assets 	under 	Administration
increased by 8% to R99 billion. Assets under
Management increased by 2% to R62.8 billion, with
linked funds placed in Discovery funds remaining
impressive at 78.3%, down slightly on the prior year
following more conservative investor allocations.
Operating profit fell by 14% to R830 million on the
back of tax changes, investment in the Invest
International launch and significant sales of
Guaranteed Plans during a high period of volatility
on the yield curve. Net inflows amounted to
R7.6 billion over the period, a decrease of 9.6%, while
new business remained resilient, growing by 2% to
R2 667 million.
Business Relevance
The strategic foundation of the business rests on strong asset
management underpinned by the Vitality Shared-Value
business model with continued enhancement of digital
capabilities. Over the period, Discovery Invest sought to
support clients, offering contribution holidays and higher
boosts and contributions. The actuarial dynamics of the
Shared-Value model in retirement planning have also been
successfully adopted in Discovery’s Umbrella Fund offering,
with a strong pipeline of committed funds. The employee
scheme, in excess of 10 000 members and R3.1 billion in
assets, transferred to the Umbrella Fund from 1 July 2020.
Discovery Invest continued to successfully apply the Shared-
Value model in the long-term savings market, with engaged
Vitality clients exhibiting 11% lower drawdowns, up to 20%
reduced withdrawals and two times more ad-hoc contributions
to their savings in comparison to the pre-launch experience in
June 2015.
The business continued to expand its retail investment market
position, being the fourth largest retail flow-taker (excluding
money market funds) during the second quarter of 2020 in SA.
In addition, Discovery Invest International partnered with
BlackRock and Goldman Sachs Asset Management to provide
access to advised portfolios of active and passive global funds
and share portfolios.
Discovery Insure
Financial Resilience
Performance was robust over the period, achieving
R246 million operating profit (including the share of
profit from CMT) – up 59% on the prior year. The
Shared-Value model proposition was evident during
this period: enhanced profitability, through reduced
claims during lockdown and favourable lapse
experience due to better-than-market client credit
profiles, was shared with clients in the form of
boosted rewards, to the value of R70 million. New
business recovered by year-end to record levels.
Gross Premium Income grew by 14% to R3.7 billion
with 6% market share, while gross new business API
grew by 5% to R1.1 billion, estimated at between
10% and 15% market share.
Business Relevance
The period under review saw the continued efficacy of the
Shared-Value business model in Discovery Insure, highlighting
the quality of the business, especially during the lockdown
period. The loss ratio for good drivers was up to 45% lower
than that of poor drivers and the lapse rate 9% lower than the
prior year – and even more so in the final quarter, reflecting
enhanced value provided to lower-risk clients. The June 2020
sales month recorded the highest gross new business annual
premium income for any month since the inception of the
business, showing strong recovery through the easing
lockdown.
Discovery Insure’s value proposition to clients and suppliers
underwent five phases of evolution, compared to one or two
in a typical year, to reaffirm its relevance in the changing
operating environment and to provide innovative solutions for
personal and commercial clients. The ability to accurately
measure driving behaviour, including distance, enabled the
business to offer an additional cash back of up to 25% of
clients’ motor comprehensive insurance premiums for driving
less. Discovery Insure also launched a world-first telematics-
based warranty cover product, creating an avenue to gain new
business from alternative parts of the automotive industry.
The commercial lines business focused on growing new
business. Gross premium income almost quadrupled, and
new business API grew by 102%, with positive lapse trends
emerging. There was also further progress in extending
Discovery Insure’s model into international markets, with a
launch planned in one of Vitality Group’s markets.

-- 8 of 56 --

7
Discovery Bank
Financial Resilience and Operational
Progress
Discovery Bank’s performance was pleasing, with
over 370 000 accounts at end June (489 000 at
13 September) and deposits of R2.4 billion
(R3.7 billion at 13 September). Total credit limits
granted were R5.5 billion of which R2.0 billion was
utilised (R9.6 billion at 13 September with R3.7 billion
utilised). The year under review represented the
first year of the Bank’s operation. Given the onset of
COVID-19, the Bank implemented three strategies,
namely; ensuring the successful migration of over
220 000 Discovery Card accounts from First National
Bank to Discovery Bank; pursuing a deposit-led
growth strategy, while ensuring the quality of the
loan book and maintaining the quantum spent on
the Bank’s build within budget; and ensuring rapid
learnings from the Shared-Value model to constantly
improve the Bank's user experience and value
proposition.
All three strategies were successfully deployed with
a system uptime of 99.9%. By the reporting date, the
migration was successfully completed and retail
deposits exceeded the loan book, resulting in the
Bank 	having 	significant 	surplus 	liquidity 	of
R3.8 billion and capital strength. The quality of
deposits was strong with 65% of deposits from
clients with a Diamond Vitality Money status. The
loan book was excellent with arrears 60% lower than
market arrears. The Bank’s value proposition has
been significantly enhanced via a more accessible
Vitality Money experience, more powerful Discovery
Miles, and a more intuitive user experience. These
enhancements will be announced at the end of
September 2020.
Business Relevance
The Bank remained resilient and relevant during COVID-19.
While average spend on client cards initially declined by 54%,
this recovered as lockdown eased, and the average deposit
rate remained constant. In addition, Discovery Bank introduced
various initiatives to support clients, including boosted
rewards, with 336 million Discovery Miles awarded over the
lockdown period. The arrears rate at end June was 5.4% and is
still considerably below the market average for credit cards.
Discovery Bank clients continued to show positive engagement:
82% of clients who activated Vitality Money have a status
higher than Blue. The shared-value principles are playing out
as expected with clients on a higher Vitality Money status
having demonstrably improved financial behaviour. Clients
with a higher status also have lower arrears rates with 0% of
Diamond status clients in arrears while Gold and Diamond
status clients save at a rate almost 11x higher than Blue status
clients.
United Kingdom
Financial Resilience
The UK business was affected by the difficult
economic and operating environment driven by
COVID-19 and persistent low interest rates, among
other elements. Over the period, in respect of the
established businesses, combined new business
reduced by 12% to £126.3 million (R2 495 million),
operating profit increased by 28% to £93.1 million
(R1 840 million) (prior to the COVID-19 reserve,
reducing by 61% to £28.2 million (R558 million) after),
while total covered lives exceeded 1.3 million, an
increase of 7%.
Business Relevance
In the UK, interest rates have been steadily declining since
Brexit, and the onset of the pandemic resulted in even greater
volatility in financial markets, adding to the complexities
brought by COVID-19. Furthermore, the pandemic led to the
NHS co-opting private hospitals to support patient treatment,
which resulted in the postponement of elective treatments.
The UK business responded quickly to these factors through
various actions and has leveraged Vitality to amplify shared
value, helping to deliver a resilient performance and position
itself for increased relevance.
The structure of the business has been adapted to deliver the
composite strategy, with several functions that span
VitalityHealth (VH) and VitalityLife (VL) in areas such as
servicing, retention, sales support and technology now
consolidated at a UK Group level. This ensures Vitality is able
to provide an integrated, intuitive service to clients and
advisers, while generating efficiencies. Vitality’s digital
capabilities including the member app, online member journey
and adviser interfaces, are also being aligned, to ensure users
have a single, consistent experience.

-- 9 of 56 --

8 Discovery Audited results for the year ended 30 June 2020
COMMENTARY continued
VitalityHealth
Financial Resilience
VH continued to deliver robust results despite the
impact of COVID-19. Operating profit grew 2% to
£42.0 million (up 9% to R830 million), which includes
the addition of a significant unearned premium
reserve (UPR) set up to better match the earning of
premiums with the expected delay in the submission
of policyholder claims to FY21. Operating profit grew
89% to £78.1 million (up 104% to R1 543 million)
before setting up this UPR adjustment. New business
declined by 15% to £62.7 million (-8% to R1 238 million)
in a challenging sales environment. Despite this,
strong retention meant that total lives reached
682 000, up 6%, while earned premiums grew 8% to
£496.8 million (up 16% to R9 813 million), before the
additional UPR. The back book was strongly cash
flow positive, generating £76.3 million in cash. After
new business acquisition costs and investment in
developing the business, VH generated a £57.6 million
cash surplus (including the additional UPR).
Business Relevance
VH looked to ensure relevance of its proposition in light of the
postponement of elective treatment due to the NHS co-opting
private hospitals and launched a cash benefit payable to
members hospitalised with COVID-19. It also broadened
access to digital healthcare services, which was already core to
its offering prior to the pandemic. Lapse rates were sustained
at low levels, showing that VH continues to deliver value in a
challenging environment.
Significant changes were necessary in the income recognition
profile, manifesting mainly through the revised release of
UPRs due to the shift in claims behaviour and timing brought
about by the co-opting of private hospitals and the limiting of
access due to COVID-19. This effectively resulted in adequate
reserves having been set aside for the anticipated claims
catch-up and higher cost of treatment (due to COVID-19
measures) as-and-when private treatment resumes.
VitalityLife (VL)
Financial Resilience
VL’s normalised operating profit before the COVID-19
provision was 52% lower at £15 million (49% lower at
R297 million). 	After the COVID-19 provision, the
normalised operating loss totalled £13.8 million
(R272 million). New business API reduced by 10% to
£63.6 million (down 3% to R1 257 million), while
earned premiums grew strongly by 11% to
£288.8 million (R5 705 million). Lives covered and in-
force policies both grew by 8%, exceeding 621 000
and 470 000 respectively.
Prior to the pandemic, VL faced challenges due to
the 	difficult 	environment 	including 	Brexit
uncertainty and persistent low interest rates in
combination with challenges relating to its lapse
experience. In response, VL initiated a plan to right-
size the business, implemented a hedge for the
low and volatile interest rate environment, and
introduced key actions to mitigate lapse risk.
COVID-19 introduced additional complexity, which
saw VL establish a provision in light of the uncertainty
around the potential impact on claims and lapses
over the next 18 months.
Business Relevance
A range of management actions are in place to return VL to
robust profitability and to right-size it for the future.
Operational actions include a significant reduction in operating
expenses, a focus on the quality of new business and enhanced
servicing and retention capabilities. These retention initiatives
were implemented to address negative lapse experience
variances, namely through increased sophistication in the
conservation strategy, strengthening of lapse assumptions,
and a revision of operational processes. As a result, lapse
experience was closer to expectation in the most recent
quarter, and continues to be monitored closely.
VL also strengthened its capital position by adapting the legal
structure of the business and deferring the Part VII transfer of
the VL back book written on the Prudential Assurance
Company’s licence by three years. The onset of COVID-19

-- 10 of 56 --

9
resulted in significant increased volatility of interest rate
markets, increasing the convexity and basis risk. Post year-
end, VL extended the duration of its interest rate hedge
swaption at a significantly lower cost than the prior one and
enhanced the hedge strategy to reduce future basis risk. This
hedge continues to protect capital, solvency, and liquidity from
the effect of lower interest rates on the whole of life portfolio.
In combination, all these actions have strengthened VL’s
capital position, lowered its cost of liquidity funding, and de-
risked it against the impact of further falls in interest rates, and
position VL for a return to growth.
Ping An Health (PAH)
Financial Resilience
PAH delivered a solid performance. Total revenue3
grew by 56% to RMB13.4 billion and new business
premium by 33% to RMB6.5 billion. This growth was
mainly driven by strong channel support for
its flagship eShengBao product and continued
persistency improvements. Sales of this product,
which lends itself to online purchase, did well during
the relatively limited COVID-19 lockdown period in
China. Profit from operations, represented by the
Group’s share of after-tax operating profit less the
costs to support the business, grew by 72% to
R182 million supported by positive investment
returns.
Business Relevance
PAH continues to gear up for considerable growth in a rapidly-
expanding healthcare market with a focus on quality business.
Continued investment and delivery were focused on three key
areas: digital and technology advancement; shared value and
product enhancement; and further embedding itself into the
Ping An Group (PAG) health ecosystem for synergistic
opportunities.
The digital healthcare evolution continued to gain momentum
with ongoing investments by Ping An Group and PAH, as well
as significant competitor activity in a very dynamic market.
PAH’s investments over the past two years into scaling online
operations as well as its app and sales and technology
capabilities positioned it well to meet the demand for more
digital interactions. PAH has full mobile user functionality,
allowing end-to-end sales processes for several products,
including eShengBao, to be completed online. This enabled
business to continue via agents or direct-to-consumer during
the COVID-19 lockdown period. In addition, this online
readiness allowed PAH to rapidly provide initiatives to increase
health awareness as well as online health services, such as
video doctor consultations. This shift towards online
interactions is a key driver in the strong growth of PAH’s app
by 145% to 29.7 million users. PAH continued to develop and
leverage technology to enhance its claims risk management,
claims processing, underwriting and sales. The individual
customer renewal rate increased by 8.3% year-on-year,
through strategies such as automatically linking deductions of
premiums and increased utilisation of a specialised sales
agents’ reapplication tool.
PAH continues to look for opportunities to embed the Shared-
Value business model more deeply. In March 2020, the
Chinese insurance regulator, CBIRC, issued new regulations
allowing for the sale of long-term medical reimbursement
products, which enables health insurers to expand their
product ranges. In August 2020, PAH obtained regulatory
approval to sell a 20-year premium-adjustable medical
reimbursement product with dynamic pricing based on the
policyholder’s health status. This marks an important
integration of Vitality (PAH’s version of Vitality is called ‘Hello
Run Club’) into a PAH product. The Shared-Value pricing
structure is key to the long-term actuarial success of the
product.
As of 1 July 2020, PAH falls within PAG’s healthcare ecosystem
and technology businesses cluster. This provides synergistic
opportunities for PAH with the other companies in the
ecosystem, such as Ping An Good Doctor (China’s largest
online 	healthcare 	services 	platform) 	and 	Ping 	An
HealthKonnect, which offers services to China’s Social Health
Insurance system.
3 Revenue includes policies written on Ping An Health’s own insurance license, as well as policies written on Ping An Life’s license and directly
reinsured to PAH based on the reinsurance treaty terms

-- 11 of 56 --

10 Discovery Audited results for the year ended 30 June 2020
COMMENTARY continued
Vitality Group
Financial Resilience
Vitality Group (VG) delivered excellent results in a
difficult period. Profit of $19.6 million (R308 million)
was up 73% from the prior year. Sales showed good
progress, with fee income growing 11% to
$72.3 million (R1.1 billion4) and insurance partners’
integrated premiums reaching $1 billion (R15.8 billion)
– an endorsement of the resilient business model
upon which the business is built. Vitality now has a
global presence across 24 markets (including the
primary markets SA and the UK). Total Vitality
membership grew to 4.1 million, of which 1.5 million
are administered on Vitality1, the globally unified
systems architecture platform. Membership from
insurance partners’ integrated products grew to
1.8 million, an increase of 29% from the prior year.
Business Relevance
NATIONAL CHAMPIONS AND FRANCHISE MARKETS
The relevance of the Vitality Shared-Value Insurance model
gained significant traction over the period with insurer
partners more strongly embedding the model into their core
strategies and ecosystems. For example, AIA embedded AIA
Vitality in its recently-announced strategy to pioneer its
Shared-Value Insurance model around health and wellness
across the Asia Pacific region. This is also manifesting in
product updates, increased engagement and integration with
Vitality1. Sumitomo Life Vitality is approaching half a million
members in Japan since launching in 2018, with exciting new
reward partnerships being concluded. The existing Generali
countries – Germany, France and Austria – were successfully
migrated onto the Vitality1 platform, and agreement was
reached to implement Vitality into additional European
markets – Italy, Generali’s home market, Spain, Poland and
Czech Republic. The Manulife Vitality portfolio is performing
well and continued to grow with the addition of new Vitality
products to its offering, and engagement exceeded
expectation. John Hancock Vitality’s overall performance also
remained strong with a 32% increase in premium income from
the prior year. On 27 August 2020, Amazon and John Hancock
announced a strategic collaboration aimed at helping
customers improve their health and wellness. The Vitality
programme played a key role in enabling John Hancock to be
the first life insurer to integrate with Amazon Halo, as part of
Amazon’s latest venture into the health and wellness space.
In terms of the Franchise markets, VG’s partnership with
Hannover Re to expand Shared-Value insurance products into
next tier markets produced pleasing results, with the total
number of signed markets at eight, of which four are live. The
review period saw launches in the Netherlands, in partnership
with a.s.r. and most recently, the second Latin American
country, Argentina, in partnership with Prudential USA. Further
launches are planned for 2020.
Vitality1 is driving rapid scaling of markets and is servicing
11 countries while maintaining high availability, delivering with
speed and accurately processing vast amounts of data. Vitality
Group has developed a reusable migration asset to migrate
from legacy to Vitality1, which will reduce implementation
costs and efforts, as well as speed up delivery. The anticipated
roll-out over the next 21 months includes nine new markets
and three new US initiatives.
Vitality USA
Vitality USA delivered a pleasing set of results, growing profits
19% from the prior year and membership by 35%. The
performance can be attributed in part to a strategic partnership
with Trustmark (an employee benefits company headquartered
in Illinois) that drove new business, and changes implemented
to optimise the sales and distribution structures. These
strategies are also expected to ensure that the strong
performance is sustained going forward and mitigate some of
the challenges expected as a result of COVID-19.
4 Excludes services related to system implementation and other cost recoveries and rewards

-- 12 of 56 --

11
Prospects for growth
Discovery’s Shared-Value business model positions it well to
deliver continued operational resilience despite the challenging
macro environment. Discovery has also provided for the
expected future financial impacts of COVID-19 on claims and
lapses to December 2021 during the 2020 financial year. The
effect of continued interest rate volatility is expected to remain
a feature of the reported results in the case of Discovery Life,
however the hedge in the UK is expected to remove the
volatility for VitalityLife. Solvency, cash and capital are not
expected to be negatively impacted by these interest rate
movements in SA; and normalised earnings will not be
impacted.
Discovery’s Ambition 2023 remains the strategic focus for the
medium-term. The Group is well positioned for growth over its
planning horizon to 2023, with the capital plan able to fund
its new initiatives. The businesses within the South African
composite have created significant insurgency and the composite
is well positioned to continue the SA growth trajectory. The UK
composite is embryonic, however the actions taken over the
period were key to ensure sustainability in the current
environment and have positioned the business to capitalise in
a normalised environment. Vitality Group through capabilities
and partnerships is well-placed to leverage the growing
acceptance of the Shared- Value business model. Ping An
Health remains committed to investing for longer-term
growth, rather than looking to extract profit or cash in the
short to medium term.
Despite the Group’s strong capital position, due to the
uncertain and potentially volatile economic environment
caused by the COVID-19 pandemic, the Discovery Board has
decided not to declare an ordinary dividend for the year ended
30 June 2020.
On behalf of the Board
ME Tucker 	A Gore
Chairperson 	Chief Executive Officer
Sandton
15 September 2020
Notes to analysts
Any forecast financial information contained in this
announcement has not been reviewed or reported on by the
company’s external auditors. Discovery has published
supplemental unaudited information on the website. For this
and other results information, go to https://www.discovery.
co.za/corporate/investor-relations and page down to Financial
results and reports, Annual results 2020.

-- 13 of 56 --

12 Discovery Audited results for the year ended 30 June 2020
STATEMENT OF FINANCIAL POSITION
for the year ended 30 June 2020
Group 	Group
June 	June
2020 	2019
R million 	Audited 	Audited
Assets
Goodwill 	5 070 	4 642
Intangible assets 	6 381 	5 597
Property and equipment 	4 643 	4 212
Assets arising from insurance contracts 	48 042 	48 781
Deferred acquisition costs 	632 	536
Assets arising from contracts with customers 	954 	752
Investment in equity-accounted investments 	2 713 	1 950
Deferred income tax 	3 511 	2 372
Financial assets
– Loans and advances to customers at amortised cost 	1 848 	–
– Investments at amortised cost 	2 523 	1 943
– Investments at fair value through profit or loss 	102 714 	90 205
– Derivative financial instruments at fair value through profit or loss 	1 370 	375
Insurance receivables, contract receivables and other non-financial receivables 	11 436 	9 015
Current income tax asset 	182 	136
Reinsurance contracts 	400 	314
Cash and cash equivalents 	17 909 	9 403
TOTAL ASSETS 	210 328 	180 233
Equity
Capital and reserves
Ordinary share capital and share premium 	10 148 	10 142
Perpetual preference share capital 	779 	779
Other reserves 	3 269 	452
Retained earnings 	30 353 	31 710
44 549 	43 083
Non-controlling interest 	4 	*
TOTAL EQUITY 	44 553 	43 083
Liabilities
Liabilities arising from insurance contracts 	82 411 	70 522
Liabilities arising from reinsurance contracts 	12 465 	10 835
Deferred income tax liability 	8 514 	8 697
Contract liabilities to customers 	808 	433
Financial liabilities
– Borrowings at amortised cost 	19 836 	14 682
– Other payables at amortised cost 	14 233 	10 262
– Deposits from customers 	2 427 	–
– Investment contracts at fair value through profit or loss 	23 012 	20 674
– Derivative financial instruments at fair value through profit or loss 	992 	509
Employee benefits 	284 	260
Current income tax liability 	793 	276
TOTAL LIABILITIES 	165 775 	137 150
TOTAL EQUITY AND LIABILITIES 	210 328 	180 233
*Amount is less than R500 000.
The order in which individual line items are presented in the Statement of financial position has been amended to better reflect their respective
liquidity, as far as possible, from least liquid to the most liquid items. No values were reclassified or restated between line items.

-- 14 of 56 --

13
INCOME STATEMENT
for the year ended 30 June 2020
Group 	Group
June 	June
2020 	2019 	%
R million 	Audited 	Audited 	change
Insurance premium revenue 	49 775 	43 036
Reinsurance premiums 	(6 308) 	(5 595)
Net insurance premium revenue 	43 467 	37 441 	16
Fee income from administration business 	11 337 	10 404
Net banking fee and commission income 	150 	–
Banking fee and commission income 	182 	–
Banking fee and commission expense 	(32) 	–
Vitality income 	3 875 	3 653
Other income 	1 100 	1 063
Investment income using the effective interest rate method 	379 	398
Net bank interest and similar income 	71 	29
Bank interest and similar income using the effective interest rate 	162 	29
Bank interest and similar expense using the effective interest rate 	(91) 	–
Net fair value gains on financial assets at fair value through profit or loss 	4 093 	4 265
Net income 	64 472 	57 253 	13
Net claims and policyholders’ benefits 	(23 246) 	(20 879)
Claims and policyholders’ benefits 	(26 856) 	(24 538)
Insurance claims recovered from reinsurers 	3 610 	3 659
Acquisition costs 	(6 547) 	(6 100)
Marketing and administration expenses 	(22 118) 	(19 954)
Amortisation of intangibles from business combinations 	(76) 	(99)
Expected credit losses 	(181) 	–
Recovery of expenses from reinsurers 	2 876 	2 830
Net transfer to/from assets and liabilities under insurance contracts 	(13 497) 	(4 706)
– change in assets arising from insurance contracts 	2 038 	5 321
– change in assets arising from reinsurance contracts 	53 	7
– change in liabilities arising from insurance contracts 	(9 418) 	(8 050)
– change in liabilities arising from reinsurance contracts 	(462) 	(1 984)
– economic assumption adjustments net of discretionary margins 	(5 708) 	–
Fair value adjustment to liabilities under investment contracts 	(151) 	(809)
Profit from operations 	1 532 	7 536 	(80)
Finance costs 	(1 568) 	(1 375)
Gain on previously held interests in DiscoveryCard business 	– 	761
Gain on dilution and disposal of equity-accounted investments 	3 	844
Impairment of goodwill 	(9) 	(17)
Foreign exchange gains 	578 	*
Share of net profits from equity-accounted investments 	264 	170
Profit before tax 	800 	7 919 	(90)
Income tax expense 	(624) 	(1 305) 	(52)
Profit for the year 	176 	6 614 	(97)
Profit/(loss) attributable to:
– ordinary shareholders 	97 	6 533 	(99)
– preference shareholders 	81 	81
– non-controlling interest 	(2) 	*
176 	6 614 	(97)
Earnings per share for profit attributable to ordinary shareholders of the
company during the year (cents):
– basic 	14.8 	1 001.5 	(99)
– diluted 	14.7 	1 001.1 	(99)
*Amount is less than R500 000.

-- 15 of 56 --

14 Discovery Audited results for the year ended 30 June 2020
STATEMENT OF OTHER COMPREHENSIVE INCOME
for the year ended 30 June 2020
Group 	Group
June 	June
2020 	2019 	%
R million 	Audited 	Audited 	change
Profit for the year 	176 	6 614 	(97)
Items that are or may be reclassified subsequently to profit or loss:
Currency translation differences 	2 800 	(140)
– unrealised gains/(losses) 	2 768 	(142)
– tax on unrealised gains/losses 	32 	2
Cash flow hedges 	(430) 	(175)
– unrealised losses 	(762) 	(91)
– tax on unrealised losses 	59 	(7)
– losses/(gains) recycled to profit or loss 	319 	(98)
– tax on recycled losses/gains 	(46) 	21
Share of other comprehensive income from equity-accounted investments 	293 	(19)
– change in fair value of debt instruments at fair value through other
comprehensive income 	3 	–
– currency translation differences 	290 	(19)
Other comprehensive income/(losses) for the year, net of tax 	2 663 	(334) 	(897)
Total comprehensive income for the year 	2 839 	6 280 	(55)
Attributable to:
– ordinary shareholders 	2 760 	6 199 	(55)
– preference shareholders 	81 	81
– non-controlling interest 	(2) 	*
Total comprehensive income for the year 	2 839 	6 280 	(55)
*Amount is less than R500 000.

-- 16 of 56 --

15
HEADLINE EARNINGS
for the year ended 30 June 2020
Group 	Group
June 	June
2020 	2019 	%
R million 	Audited 	Audited 	change
Earnings per share (cents):
– basic 	14.8 	1 001.5 	(99)
– diluted 	14.7 	1 001.1 	(99)
Headline earnings per share (cents):
– basic 	45.0 	789.0 	(94)
– diluted 	44.7 	788.7 	(94)
Normalised headline earnings per share (cents):
– basic 	570.7 	771.9 	(26)
– diluted 	566.7 	771.6 	(27)
The reconciliation between earnings and headline earnings is shown below:
Net profit attributable to ordinary shareholders 	97 	6 533 	(99)
Adjusted for:
– derecognition of intangible assets and property and equipment, net of tax 	149 	–
– gain on dilution and disposal of equity-accounted investments, net of tax 	(3) 	(666)
– gain on disposal of property and equipment, net of capital gains tax 	(2) 	1
– gain on previously held interests in DiscoveryCard business 	– 	(761)
– impairment of goodwill 	9 	17
– impairment of intangible assets, net of tax 	44 	23
– Discovery Limited’s share of headline earnings adjustments made by
equity-accounted investees:
– derecognition of intangible assets and property and equipment, net of tax 	2 	–
Headline earnings 	296 	5 147 	(94)
Adjusted for:
– economic assumptions adjustments net of discretionary margins and interest
rate derivative, net of tax 	3 584 	–
– economic assumption adjustment net of discretionary margin, net of tax 	4 295 	–
– fair value gains on VitalityLife interest rate derivative, net of tax 	(711) 	–
– other 	(133) 	(112)
– amortisation of intangibles from business combinations, net of tax 	60 	84
– costs relating to disposal of equity-accounted investments, net of tax 	– 	15
– debt restructuring costs resulting from DiscoveryCard joint venture transaction 	– 	33
– deferred tax asset raised on assessed losses 	(275) 	(326)
– deferred tax related to Discovery Life ‘new adjusted IFRS basis’ and Corporate 	– 	(38)
Policyholder Fund assessed loss 	– 	(38)
– initial expenses related to Prudential Book transfer, net of tax 	57 	23
– restructuring costs, net of tax 	80 	–
– time value of money movement of swaption contract in VitalityLife, net of tax 	97 	–
– transaction costs related to VitalityLife interest rate derivative, net of tax 	37 	–
– unrealised (gains)/losses on foreign exchange contracts not designated
as hedges, net of tax 	(189) 	97
Normalised headline earnings 	3 747 	5 035 	(26)
Weighted number of shares in issue (000’s) 	656 648 	652 295
Diluted weighted number of shares (000’s) 	661 242 	652 568
Normalised headline earnings is calculated by adjusting headline earnings with significant items that are not considered to be part of Discovery’s
normal operations. These adjustments include those gains or losses associated with changes in economic assumptions recognised in profit or loss,
net of available discretionary margin, and net of any gains or losses on derivatives entered into to offset such changes in economic assumptions.
Adjustments are shown net of tax.

-- 17 of 56 --

16 Discovery Audited results for the year ended 30 June 2020
STATEMENT OF CHANGES IN EQUITY
at 30 June 2020
Attributable to equity holders of the Company
R million
Share capital
and share
premium
Preference
share
capital
Share-based
payment
reserve
Year ended 30 June 2020
At beginning of the year 	10 142 	779 	41
IFRS transitional adjustments 	– 	– 	–
Adjusted balance at beginning of the year 	10 142 	779 	41
Total comprehensive income for the year 	– 	81 	–
Profit for the year 	– 	81 	–
Other comprehensive income 	– 	– 	–
Transactions with owners 	6 	(81) 	154
Delivery of treasury shares 	10 	– 	(10)
Increase in treasury shares 	(4) 	– 	–
Acquisition of subsidiaries with non-controlling interest 	– 	– 	–
Employee share option schemes:
– Value of employee services 	– 	– 	164
Dividends paid to preference shareholders 	– 	(81) 	–
Dividends paid to ordinary shareholders 	– 	– 	–
At end of the year 	10 148 	779 	195
Year ended 30 June 2019
Balance at beginning of the year 	8 308 	779 	327
Total comprehensive income for the year 	– 	81 	–
Profit for the year 	– 	81 	–
Other comprehensive income 	– 	– 	–
Transactions with owners 	1 834 	(81) 	(286)
Share issue 	1 854 	– 	–
Share issue costs 	(19) 	– 	–
Change in ownership without change in control 	– 	– 	–
Increase in treasury shares 	(5) 	– 	–
Delivery of treasury shares 	4 	– 	–
Transfer of vested equity-settled share schemes 	– 	– 	(319)
Employee share option schemes:
– Value of employee services 	– 	– 	33
Dividends paid to preference shareholders 	– 	(81) 	–
Dividends paid to ordinary shareholders 	– 	– 	–
At end of the year 	10 142 	779 	41
1 This relates to fair value adjustments on those equity instruments designated at fair value through other comprehensive income and
those debt instruments measured at fair value through other comprehensive income.
* Amount is less than R500 000.

-- 18 of 56 --

17
Attributable to equity holders of the Company
Investment
reserve1
Foreign
currency
translation
reserve
Hedging
reserve
Retained
earnings 	Total
Non-controlling
interest 	Total
– 	585 	(174) 	31 710 	43 083 	* 	43 083
– 	– 	– 	(41) 	(41) 	– 	(41)
– 	585 	(174) 	31 669 	43 042 	* 	43 042
3 	3 090 	(430) 	97 	2 841 	(2) 	2 839
– 	– 	– 	97 	178 	(2) 	176
3 	3 090 	(430) 	– 	2 663 	– 	2 663
– 	– 	– 	(1 413) 	(1 334) 	6 	(1 328)
– 	– 	– 	– 	– 	– 	–
– 	– 	– 	– 	(4) 	– 	(4)
– 	– 	– 	– 	– 	6 	6
– 	– 	– 	– 	164 	– 	164
– 	– 	– 	– 	(81) 	– 	(81)
– 	– 	– 	(1 413) 	(1 413) 	– 	(1 413)
3 	3 675 	(604) 	30 353 	44 549 	4 	44 553
– 	744 	1 	27 362 	37 521 	* 	37 521
– 	(159) 	(175) 	6 533 	6 280 	* 	6 280
– 	– 	– 	6 533 	6 614 	– 	6 614
– 	(159) 	(175) 	– 	(334) 	– 	(334)
– 	– 	– 	(2 185) 	(718) 	– 	(718)
– 	– 	– 	– 	1 854 	– 	1 854
– 	– 	– 	– 	(19) 	– 	(19)
– 	– 	– 	(1 104) 	(1 104) 	– 	(1 104)
– 	– 	– 	– 	(5) 	– 	(5)
– 	– 	– 	– 	4 	– 	4
– 	– 	– 	319 	– 	– 	–
– 	– 	– 	– 	33 	– 	33
– 	– 	– 	– 	(81) 	– 	(81)
– 	– 	– 	(1 400) 	(1 400) 	– 	(1 400)
– 	585 	(174) 	31 710 	43 083 	* 	43 083

-- 19 of 56 --

18 Discovery Audited results for the year ended 30 June 2020
STATEMENT OF CASH FLOWS
for the year ended 30 June 2020
Group 	Group
June 	June
2020 	2019
R million 	Audited 	Audited
Cash flow from operating activities 	8 065 	1 738
Cash generated by operations 	17 372 	12 154
Purchase of investments held to back policyholder liabilities 	(37 316) 	(35 109)
Proceeds from disposal of investments held to back policyholder liabilities 	26 218 	23 831
Working capital changes 	1 628 	625
7 902 	1 501
Dividends received 	342 	339
Interest received 	2 516 	2 274
Interest paid 	(1 406) 	(1 219)
Taxation paid 	(1 289) 	(1 157)
Cash flow from investing activities 	(3 030) 	(2 844)
Purchase of financial assets 	(26 497) 	(21 724)
Proceeds from disposal of financial assets 	25 532 	21 830
Purchase of property and equipment 	(290) 	(510)
Proceeds from disposal of property and equipment 	4 	95
Purchase of software and other intangible assets 	(1 726) 	(1 999)
Proceeds from disposal of intangible assets 	– 	22
Proceeds from the disposal of equity-accounted investments 	– 	402
Acquisition of business net of cash 	16 	(736)
Additional investment in equity-accounted investments 	(69) 	(224)
Cash flow from financing activities 	2 202 	(344)
Proceeds from issuance of ordinary shares 	– 	1 854
Shares issue costs 	– 	(19)
Acquisition of additional interest in subsidiary 	– 	(1 104)
Purchase of treasury shares 	(4) 	–
Dividends paid to ordinary shareholders 	(1 413) 	(1 400)
Dividends paid to preference shareholders 	(81) 	(81)
Proceeds from borrowings 	10 339 	2 147
Repayment of borrowings 	(6 639) 	(1 741)
Net increase/(decrease) in cash and cash equivalents 	7 237 	(1 450)
Cash and cash equivalents at beginning of the year 	9 403 	10 888
Exchange gains/(losses) on cash and cash equivalents 	1 269 	(35)
Cash and cash equivalents at end of the year 	17 909 	9 403

-- 20 of 56 --

19
ADDITIONAL INFORMATION
at 30 June 2020
FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS
The Group’s financial instruments measured at fair value have been disclosed using a fair value hierarchy. The hierarchy has three
levels that reflect the significance of the inputs used in measuring fair value. These are as follows:
Level 1 includes financial instruments that are measured using unadjusted, quoted prices in an active market for identical financial
instruments. Quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or
regulatory agency and those prices represent actual and regularly occurring market transactions on an arm’s length basis.
Level 2 includes financial instruments that are valued using techniques based significantly on observable market data. Instruments
in this category are valued using:
(a) quoted prices for similar instruments or identical instruments in markets which are not considered to be active or
(b) valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly based on
observable market data.
Level 3 includes financial instruments that are valued using valuation techniques that incorporate information other than
observable market data and where at least one input (which could have a significant effect on instruments’ valuation) cannot be
based on observable market data.
30 June 2020
R million (audited) 	Level 1 	Level 2 	Level 3 	Total
Financial assets
Financial assets at fair value through profit or loss:
– Equity securities 	32 953 	120 	– 	33 073
– Equity linked notes 	– 	2 318 	– 	2 318
– Debt securities 	29 965 	1 708 	– 	31 673
– Inflation linked securities 	1 332 	156 	– 	1 488
– Money market securities 	2 688 	10 289 	– 	12 977
– Mutual funds 	21 185 	– 	– 	21 185
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	14 	– 	14
– not designated as hedging instruments 	– 	1 356 	– 	1 356
Total financial assets 	88 123 	15 961 	– 	104 086
Financial liabilities
Investment contracts at fair value through profit and loss 	– 	23 012 	– 	23 012
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	854 	– 	854
– not designated as hedging instruments 	– 	138 	– 	138
Total financial liabilities 	– 	24 004 	– 	24 004
There were no transfers between level 1 and 2 during the current financial period.

-- 21 of 56 --

ADDITIONAL INFORMATION continued
at 30 June 2020
20 Discovery Audited results for the year ended 30 June 2020
FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS continued
Specific valuation techniques used to value financial instruments in level 2
❚ 	Discovery has invested in equity linked notes offered by international banks in order to back certain unit-linked contract
liabilities. The calculation of the daily value of the equity linked investments is made by the provider of the note. Discovery has
procedures in place to ensure that these prices are correct. Aside from the daily reasonableness checks versus similar funds and
movement since the prior day’s price, the fund values are calculated with reference to a specific formula or index, disclosed to
the policyholders, which is recalculated by Discovery in order to confirm that the price provided by the provider is correct.
❚ 	If a quoted market price is not available on a recognised stock exchange or from a broker for non-exchange traded financial
instruments, the fair value of the instrument is estimated by the asset managers, using valuation techniques including the use
of recent arm’s length market transactions, reference to the current fair value of another instrument that is substantially the
same, discounted cash flow techniques, option pricing models or other valuation techniques that provide a reliable estimate of
prices obtained in actual market transactions.
❚ 	The fair value of the hedged derivatives is calculated as follows:
(a) The fair value of call options is calculated on a Black-Scholes model.
(b) The fair value of the return swaps is calculated by discounting the future cash flows of the instruments.
(c) The fair value of interest rate swaps is calculated as the present value of the estimated future cash flows based on
observable yield curves.
30 June 2019
R million (audited) 	Level 1 	Level 2 	Level 3 	Total
Financial assets
Financial assets at fair value through profit or loss:
– Equity securities 	33 966 	1 015 	– 	34 981
– Equity linked notes 	23 	3 178 	– 	3 201
– Debt securities 	19 531 	1 599 	– 	21 130
– Inflation linked securities 	554 	– 	– 	554
– Money market securities 	7 362 	6 403 	– 	13 765
– Mutual funds 	16 574 	– 	– 	16 574
Derivative financial instruments at fair value: 	–
– used as cash flow hedges 	– 	176 	– 	176
– not designated as hedging instruments 	– 	199 	– 	199
Total financial assets 	78 010 	12 570 	– 	90 580
Financial liabilities
Investment contracts at fair value through profit and loss 	– 	20 674 	– 	20 674
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	250 	– 	250
– not designated as hedging instruments 	– 	259 	– 	259
Total financial liabilities 	– 	21 183 	– 	21 183

-- 22 of 56 --

21
Exchange rates used in the preparation of these results
USD 	GBP
30 June 2020
– Average 	15.70 	19.75
– Closing 	17.41 	21.44
30 June 2019
– Average 	14.17 	18.32
– Closing 	14.15 	17.98

-- 23 of 56 --

22 Discovery Audited results for the year ended 30 June 2020
SEGMENTAL INFORMATION
for the year ended 30 June 2020
R million
SA
Health
SA
Life
SA
Invest
SA
Insure 2,3
30 June 2020
Income statement
Insurance premium revenue 	252 	12 984 	15 602 	3 544
Reinsurance premiums 	(1) 	(2 564) 	– 	(66)
Net insurance premium revenue 	251 	10 420 	15 602 	3 478
Fee income from administration businesses 	7 238 	– 	2 246 	12
Net banking fee and commission income 	– 	– 	– 	–
Banking fee and commission income 	– 	– 	– 	–
Banking fee and commission expense 	– 	– 	– 	–
Vitality income 	– 	– 	– 	–
Other income 	883 	39 	– 	–
Investment income earned on assets backing policyholder liabilities 	– 	13 	– 	119
Net bank interest and similar income 	– 	– 	– 	–
Bank interest and similar income using the effective interest rate 	– 	– 	– 	–
Bank interest and similar expense using the effective interest rate 	– 	– 	– 	–
Finance charge on negative reserve funding 	– 	– 	– 	–
Inter-segment funding1 	– 	(762) 	762 	–
Net fair value gains on financial assets at fair value through profit or loss 	(20) 	867 	834 	32
Net income 	8 352 	10 577 	19 444 	3 641
Net claims and policyholders’ benefits 	(100) 	(6 079) 	(10 542) 	(1 915)
Claims and policyholders’ benefits 	(100) 	(7 926) 	(10 542) 	(1 939)
Insurance claims recovered from reinsurers 	– 	1 847 	– 	24
Acquisition costs 	(30) 	(1 566) 	(1 080) 	(479)
Credit impairment charges 	– 	– 	– 	–
Marketing and administration expenses
– depreciation and amortisation 	(176) 	(7) 	(9) 	(84)
– derecognition of intangible assets and property and equipment 	(29) 	– 	– 	(74)
– impairment of intangible assets 	– 	– 	– 	–
– other expenses 	(4 844) 	(1 976) 	(984) 	(824)
Recovery of expenses from reinsurers 	– 	– 	– 	–
Transfer from assets/liabilities under insurance contracts
– change in assets arising from insurance contracts 	– 	1 557 	– 	–
– change in assets arising from reinsurance contracts 	– 	27 	– 	7
– change in liabilities arising from insurance contracts 	– 	(238) 	(5 809) 	(39)
– change in liabilities arising from reinsurance contracts 	– 	678 	– 	–
Fair value adjustment to liabilities under investment contracts 	– 	(2) 	(190) 	–
Share of net profits from equity-accounted investments 	17 	– 	– 	13
Normalised profit/(loss) from operations 	3 190 	2 971 	830 	246
Investment income earned on shareholder investments and cash 	65 	21 	45 	10
Economic assumptions adjustments net of discretionary margins and
interest rate derivative 	– 	(3 635) 	– 	–
Economic assumptions adjustments net of discretionary margins 	– 	(3 635) 	– 	–
Fair value gains on VitalityLife interest rate derivative 	– 	– 	– 	–
Net fair value gains/(losses) on financial assets at fair value through
profit or loss 	– 	128 	4 	–
Restructuring costs 	– 	– 	– 	–
Gains from dilution of equity-accounted investments 	– 	– 	– 	3
Impairment of goodwill 	– 	– 	– 	–
Initial expenses related to Prudential Book transfer 	– 	– 	– 	–
Transaction costs related to VitalityLife interest rate derivatives 	– 	– 	– 	–
Amortisation of intangibles from business combinations 	– 	– 	– 	–
Market rentals related to Head Office building adjusted for finance costs
and depreciation 	– 	– 	– 	–
Finance costs 	(286) 	– 	– 	–
Foreign exchange gains 	15 	– 	36 	–
Profit before tax 	2 984 	(515) 	915 	259
Income tax expense 	(826) 	147 	(256) 	(64)
Profit for the year 	2 158 	(368) 	659 	195
1 The intersegment funding of R762 million reflects a notional allocation of interest earned on the negative reserve bacNing policyholdersȇ funds of
guaranteed investment products and hence is transferred to Discovery Invest.
2 During the current financial year segmental information has been changed to align with the change in reportable segments, i.e. Discovery Insure
(South Africa) and Discovery Bank (South Africa) are now shown as separate segments. The comparative information has been restated accordingly.
3 This segment relates to Discovery Insure – Personal lines only.
· The segment information is presented on the same basis as reported to the Chief Executive 2fficers of the reportable segments. The segment total
is then adjusted for accounting reclassifications and entries required to produce IFRS compliant results. These adjustments include the following:

-- 24 of 56 --

23
Ȃ The VitalityLife results, for business originally written on the Prudential Assurance Company license, are reclassified to account for the
contractual arrangement as a reinsurance contract under IFRS 4.
– The Discovery Unit Trusts (DUT) are consolidated into Discovery’s results for IFRS purposes. The IFRS reporting adjustments include the effects
of consolidating the unit trusts into Discovery’s results, effectively being the income and expenses relating to units held by third parties.
– The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments.
SA
Vitality
SA
Bank2
UK
Health
UK
Life
All other
segments
Segment
total
IFRS reporting
adjustments4
IFRS
total
– 	– 	9 100 	5 705 	3 330 	50 517 	(742) 	49 775
– 	– 	(1 589) 	(2 789) 	(41) 	(7 050) 	742 	(6 308)
– 	– 	7 511 	2 916 	3 289 	43 467 	– 	43 467
– 	137 	30 	– 	1 687 	11 350 	(13) 	11 337
– 	150 	– 	– 	– 	150 	– 	150
– 	182 	– 	– 	– 	182 	– 	182
– 	(32) 	– 	– 	– 	(32) 	– 	(32)
2 401 	121 	452 	212 	689 	3 875 	– 	3 875
– 	120 	69 	– 	18 	1 129 	(29) 	1 100
– 	1 	9 	37 	1 	180 	(180) 	–
– 	63 	– 	– 	– 	63 	8 	71
– 	162 	– 	– 	– 	162 	– 	162
– 	(99) 	– 	– 	– 	(99) 	8 	(91)
– 	– 	– 	(838) 	– 	(838) 	838 	–
– 	– 	– 	– 	– 	– 	– 	–
(2) 	92 	29 	768 	59 	2 659 	1 434 	4 093
2 399 	684 	8 100 	3 095 	5 743 	62 035 	2 058 	64 093
– 	– 	(3 623) 	(798) 	(189) 	(23 246) 	– 	(23 246)
– 	– 	(4 796) 	(1 964) 	(229) 	(27 496) 	640 	(26 856)
– 	– 	1 173 	1 166 	40 	4 250 	(640) 	3 610
(66) 	– 	(797) 	(1 814) 	123 	(5 709) 	(838) 	(6 547)
– 	(181) 	– 	– 	– 	(181) 	– 	(181)
– 	–
(15) 	(236) 	(359) 	(46) 	(612) 	(1 544) 	(210) 	(1 754)
(9) 	– 	– 	– 	(84) 	(196) 	– 	(196)
– 	– 	– 	– 	(63) 	(63) 	– 	(63)
(2 302) 	(1 438) 	(3 297) 	(2 063) 	(2 625) 	(20 353) 	260 	(20 093)
– 	– 	826 	2 050 	– 	2 876 	– 	2 876
– 	– 	– 	(2 788) 	29 	(1 202) 	3 240 	2 038
– 	– 	8 	11 	– 	53 	– 	53
– 	– 	(28) 	(18) 	(3 110) 	(9 242) 	(176) 	(9 418)
– 	– 	– 	2 099 	– 	2 777 	(3 239) 	(462)
– 	– 	– 	– 	4 	(188) 	37 	(151)
– 	– 	– 	– 	222 	252 	– 	252
7 	(1 171) 	830 	(272) 	(562) 	6 069 	1 132 	7 201
27 	– 	1 	12 	746 	927 	(548) 	379
– 	– 	– 	(1 195) 	– 	(4 830) 	(878) 	(5 708)
– 	– 	– 	(2 073) 	– 	(5 708) 	– 	(5 708)
– 	– 	– 	878 	– 	878 	(878) 	–
– 	– 	– 	(120) 	263 	275 	(275) 	–
– 	– 	– 	(100) 	– 	(100) 	100 	–
– 	– 	– 	– 	– 	3 	– 	3
– 	– 	– 	– 	(9) 	(9) 	– 	(9)
– 	– 	– 	(71) 	– 	(71) 	71 	–
– 	– 	– 	(45) 	– 	(45) 	45 	–
– 	– 	– 	– 	(76) 	(76) 	– 	(76)
– 	– 	– 	– 	(259) 	(259) 	259 	–
– 	– 	(7) 	(257) 	(1 389) 	(1 939) 	371 	(1 568)
– 	– 	– 	– 	527 	578 	– 	578
34 	(1 171) 	824 	(2 048) 	(759) 	523 	277 	800
(10) 	270 	(129) 	239 	282 	(347) 	(277) 	(624)
24 	(901) 	695 	(1 809) 	(477) 	176 	– 	176

-- 25 of 56 --

24 Discovery Audited results for the year ended 30 June 2020
SEGMENTAL INFORMATION
for the year ended June 2019
R million
SA
Health
SA
Life
SA
Invest
SA
Insure2
30 June 2019
Income statement
Insurance premium revenue 	167 	12 131 	14 267 	3 158
Reinsurance premiums 	(1) 	(2 410) 	– 	(261)
Net insurance premium revenue 	166 	9 721 	14 267 	2 897
Fee income from administration businesses 	6 815 	– 	2 050 	12
Vitality income 	– 	– 	– 	–
Other income 	782 	42 	– 	–
Investment income earned on assets backing policyholder liabilities 	– 	14 	1 	142
Net bank interest and similar income 	– 	– 	– 	–
Bank interest and similar income using the effective interest rate 	– 	– 	– 	–
Bank interest and similar expense using the effective interest rate 	– 	– 	– 	–
Finance charge on negative reserve funding 	– 	– 	– 	–
Inter-segment funding1 	– 	(754) 	754 	–
Net fair value gains on financial assets at fair value through
profit or loss 	7 	1 056 	1 849 	–
Net income 	7 770 	10 079 	18 921 	3 052
Net claims and policyholders’ benefits 	(64) 	(6 037) 	(8 989) 	(1 734)
Claims and policyholders’ benefits 	(65) 	(8 205) 	(8 989) 	(1 903)
Insurance claims recovered from reinsurers 	1 	2 168 	– 	169
Acquisition costs 	(6) 	(1 705) 	(1 138) 	(405)
Marketing and administration expenses
– depreciation and amortisation 	(223) 	(4) 	(4) 	(70)
– impairment of intangibles assets 	(4) 	– 	–
– other expenses 	(4 423) 	(1 876) 	(904) 	(745)
Recovery of expenses from reinsurers 	– 	– 	– 	–
Transfer from assets/liabilities under insurance contracts
– change in assets arising from insurance contracts 	– 	3 475 	– 	–
– change in assets arising from reinsurance contracts 	– 	10 	– 	(5)
– change in liabilities arising from insurance contracts 	(9) 	(251) 	(6 837) 	53
– change in liabilities arising from reinsurance contracts 	– 	(458) 	– 	–
Fair value adjustment to liabilities under investment contracts 	– 	(3) 	(83) 	–
Share of net profits from equity-accounted investments 	3 	– 	– 	8
Normalised profit/(loss) from operations 	3 044 	3 230 	966 	155
Investment income earned on shareholder investments and cash4 	57 	8 	35 	30
Net fair value gains/(losses) on financial assets at fair value through
profit or loss 	– 	224 	(9) 	–
Gains from dilution of equity accounted investments 	– 	– 	– 	808
Gain on previously held interests in DiscoveryCard business 	– 	– 	– 	–
Impairment of goodwill 	– 	– 	– 	–
Initial expenses related to Prudential Book transfer 	– 	– 	– 	–
Amortisation of intangibles from business combinations 	– 	– 	– 	–
Market rentals related to Head Office building adjusted for
finance costs and depreciation 	– 	– 	– 	–
Finance costs4 	(270) 	(2) 	– 	–
Foreign exchange gains/(losses) 	1 	– 	6 	–
Profit before tax 	2 832 	3 460 	998 	993
Income tax expense 	(741) 	(880) 	(280) 	(195)
Profit for the period 	2 091 	2 580 	718 	798
΂ 	The intersegment funding of R754 million reflects a notional allocation of interest earned on the negative reserve bacNing policyholdersȇ funds of
guaranteed investment products and hence is transferred to Discovery Invest.
2 This segment relates to Discovery Insure – Personal lines only.
Ά The segment information is presented on the same basis as reported to the Chief Executive 2fficers of the reportable segments. The segment total
is then adjusted for accounting reclassifications and entries required to produce IFRS compliant results. These adjustments include the following:

-- 26 of 56 --

25
Ȃ The VitalityLife results, for business originally written on the Prudential Assurance Company license, are reclassified to account for the
contractual arrangement as a reinsurance contract under IFRS 4.
– The Discovery Unit Trusts (DUT) are consolidated into Discovery’s results for IFRS purposes. The IFRS reporting adjustments include the effects
of consolidating the unit trusts into Discovery’s results, effectively being the income and expenses relating to units held by third parties.
– The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments.
· These line items have been restated to include intercompany investment income and finance costs respectively, in line with current year disclosure.
In the prior year these items were eliminated in the various segments.
SA
Vitality
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
IFRS reporting
adjustments3
IFRS
total
– 	– 	8 429 	4 750 	801 	43 703 	(667) 	43 036
– 	– 	(1 393) 	(2 177) 	(20) 	(6 262) 	667 	(5 595)
– 	– 	7 036 	2 573 	781 	37 441 	– 	37 441
– 	219 	15 	– 	1 311 	10 422 	(18) 	10 404
2 329 	120 	501 	157 	546 	3 653 	– 	3 653
– 	224 	39 	– 	(2) 	1 085 	(22) 	1 063
– 	– 	10 	42 	(1) 	208 	(208) 	–
– 	29 	– 	– 	– 	29 	– 	29
– 	29 	– 	– 	– 	29 	– 	29
– 	– 	– 	– 	– 	– 	– 	–
– 	– 	– 	(243) 	– 	(243) 	243 	–
– 	– 	– 	– 	– 	– 	– 	–
– 	– 	40 	211 	32 	3 196 	1 069 	4 265
2 329 	592 	7 641 	2 740 	2 667 	55 791 	1 064 	56 855
– 	– 	(3 525) 	(513) 	(17) 	(20 879) 	– 	(20 879)
– 	– 	(4 613) 	(1 133) 	(30) 	(24 938) 	400 	(24 538)
– 	– 	1 088 	620 	13 	4 059 	(400) 	3 659
(87) 	(14) 	(732) 	(1 888) 	118 	(5 857) 	(243) 	(6 100)
(8) 	(51) 	(251) 	(34) 	(399) 	(1 044) 	(210) 	(1 254)
(5) 	– 	– 	– 	(23) 	(32) 	– 	(32)
(2 169) 	(823) 	(3 148) 	(2 060) 	(2 458) 	(18 605) 	(63) 	(18 668)
– 	– 	814 	2 016 	– 	2 830 	– 	2 830
– 	– 	– 	1 570 	(4) 	5 041 	280 	5 321
– 	– 	(8) 	10 	– 	7 	– 	7
– 	– 	(33) 	(17) 	(791) 	(7 885) 	(165) 	(8 050)
– 	– 	– 	(1 246) 	– 	(1 704) 	(280) 	(1 984)
– 	– 	– 	– 	– 	(86) 	(723) 	(809)
– 	– 	– 	– 	159 	170 	– 	170
60 	(296) 	758 	578 	(748) 	7 747 	(340) 	7 407
42 	– 	1 	14 	635 	822 	(424) 	398
– 	– 	– 	– 	(144) 	71 	(71) 	–
– 	– 	– 	– 	15 	823 	21 	844
– 	– 	– 	– 	761 	761 	– 	761
– 	– 	– 	– 	(17) 	(17) 	– 	(17)
– 	– 	– 	(28) 	– 	(28) 	28 	–
– 	– 	– 	– 	(99) 	(99) 	– 	(99)
– 	– 	– 	– 	(281) 	(281) 	281 	–
– 	– 	– 	(210) 	(1 185) 	(1 667) 	292 	(1 375)
– 	– 	– 	– 	(7) 	– 	– 	–
102 	(296) 	759 	354 	(1 070) 	8 132 	(213) 	7 919
(29) 	113 	(38) 	(138) 	670 	(1 518) 	213 	(1 305)
73 	(183) 	721 	216 	(400) 	6 614 	– 	6 614

-- 27 of 56 --

26 Discovery Audited results for the year ended 30 June 2020
REVIEW OF GROUP RESULTS
for the year ended 30 June 2020
NEW BUSINESS ANNUALISED PREMIUM INCOME
The new business annualised premium income (API) set out below provides a view of the scale of new business across all operations
of the Group and does not necessarily reflect the new business attributable to the legal entities within the Group. For instance,
Discovery Health Medical Scheme’s (DHMS) new business is attributable to the medical scheme but is under the administration and
marketing of Discovery Health which earns a fee in respect of such services.
Core new business API increased by 5% for the year ended 30 June 2020 when compared to the same period in the prior year.
R million
June
2020
June
2019
%
change
Discovery Health1 	6 101 	6 670 	(9)
Discovery Life 	2 286 	2 312 	(1)
Discovery Invest 	2 667 	2 604 	2
Discovery Insure 	1 089 	1 041 	5
Discovery Vitality 	135 	161 	(16)
VitalityHealth 	1 238 	1 346 	(8)
VitalityLife 	1 257 	1 291 	(3)
Ping An Health (25% interest) 	3 575 	2 518 	42
Other new businesses2 	825 	386 	114
Core new business API of Group 	19 173 	18 329 	5
New Closed Schemes1 	– 	25 	(100)
New business API of Group including new Closed Schemes 	19 173 	18 354 	4
Gross revenue Vitality Group3 	1 134 	922 	23
Total new business API and other new business 	20 307 	19 276 	5
The number of new clients to Discovery Bank as at 30 June 2020 was 45 916 (2019: 197), with average customer advances of R20 500
for the year ended 30 June 2020.
1 1ew business API for Discovery Health includes new business API for all businesses administered by Discovery Health, including DHMS, Closed
Schemes and offerings such as *AP cover and Primary Care cover. The comparative has been restated by R30 million to include new business API
from *AP cover. The new business API for 1ew Closed Schemes includes contracted new business API and business in the first twelve months of
onboarding. Closed Schemes refer to those restricted to certain employers and industries.
2 2ther new businesses include the Umbrella Fund, Discovery Insure commercial and VitalityInvest.
3 Vitality Group new business includes gross recurring and lump sum revenues earned by Vitality Group and specifically excludes revenue related
to cost recoveries and rewards.
Calculation of new business API
New business API is calculated at 12 times the monthly premium for new recurring premium policies and 10% of the value of new
single premium policies. It also includes both automatic premium increases and servicing increases on existing long-term insurance
policies. The amounts exclude indirect taxes.
The new business API in the table above differs from the new business API disclosed in the embedded value largely as a result of:
❚ 	The timing of inclusion of policyholders in the calculation of new business API – In the embedded value, new business is included
from the earlier of the date that the first premium has been received or when the policy is on risk, whereas in the table above,
new business is included when the policy has been contractually committed.
❚ 	Inclusion of automatic premium increases and servicing increases on existing life policies – These are included in the table above but
excluded in the embedded value API values disclosed.
Refer to the footnotes to Table 7: Embedded Value of New Business for a more detailed description of the differences in new
business disclosures between the embedded value and the table above.

-- 28 of 56 --

27
GROSS INFLOWS UNDER MANAGEMENT
Gross inflows under management measures the total funds collected by Discovery. Gross inflows under management increased by
11% for the year ended 30 June 2020 when compared to the same period in the prior year.
R million
June
2020
June
2019
%
change
Discovery Health 	89 682 	82 148 	9
Discovery Life 	13 023 	12 173 	7
Discovery Invest 	24 501 	22 132 	11
Discovery Insure 	3 556 	3 198 	11
Discovery Vitality 	2 401 	2 329 	3
VitalityHealth 	9 651 	8 984 	7
VitalityLife 	5 917 	4 907 	21
All other businesses 	6 102 	3 191 	91
Gross inflows under management 	154 833 	139 062 	11
Less: collected on behalf of third parties 	(87 962) 	(80 199) 	10
Discovery Health 	(81 309) 	(74 384) 	9
Discovery Invest 	(6 653) 	(5 815) 	14
Gross income of Group per the segmental information 	66 871 	58 863 	14
Gross income is made up as follows:
– Insurance premium revenue 	50 517 	43 703 	16
– Fee income from administration businesses 	11 350 	10 422 	9
– Vitality income 	3 875 	3 653 	6
– Other income 	1 129 	1 085 	4
Gross income of Group per the segmental information 	66 871 	58 863 	14

-- 29 of 56 --

28 Discovery Audited results for the year ended 30 June 2020
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2020
NORMALISED PROFIT FROM OPERATIONS
The following table shows the main components of the normalised profit from operations for the year ended 30 June 2020:
R million
June
2020
June
2019
%
change
Discovery Health 	3 190 	3 044 	5
Discovery Life 	2 971 	3 230 	(8)
Discovery Invest 	830 	966 	(14)
Discovery Vitality 	7 	60 	(88)
VitalityHealth 	830 	758 	9
VitalityLife 	(272) 	578 	(147)
Normalised profit from established businesses 	7 556 	8 636 	(13)
Emerging businesses 	736 	422 	74
– Discovery Insure 	246 	155 	59
– Vitality Group including Ping An Health 	490 	267 	84
Development and other segments 	(2 223) 	(1 311) 	70
– Discovery Bank 	(1 171) 	(296) 	(296)
– Other new initiatives 	(1 052) 	(1 015) 	(4)
Normalised profit from operations 	6 069 	7 747 	(22)
movements. For Discovery, COVID-19 has created a uniquely-
complex operating and economic environment, with pressure
on new business, lapse rates, and potential future claims as
well as volatility in interest rates and investment returns.
The most significant impact on the Discovery business has
been:
❚ 	The creation of significant provisions and reserves for expected
future COVID-19 effects where appropriate; and
❚ 	Materially volatile long-term interest rates in both South Africa
(SA) and the United Kingdom (UK) which negatively affected
earnings.
Significant provision for expected future
COVID-19 effects
Discovery has reserved R3.4 billion (R2.3 billion net of
discretionary margin offset), for both future claims and lapses
as a result of the COVID-19 pandemic. This estimation reflects
management’s best estimate of the impact as at 30 June 2020.
It ensures that, on the Group’s expected scenario, all claims and
economic effects of the pandemic are carried entirely in the
financial year ended 30 June 2020.
Discovery calculated its COVID-19 provisions to estimate the
future mortality, morbidity and economic effects of the
pandemic by estimating excess mortality and excess lapses
expected to arise in 2021 and 2022 on a variety of scenarios by
setting a stressed, central (prudent best estimate) and light
scenario. The central scenario has been used to set the
provision, while the stressed scenario was used to test capital
Emerging businesses are those businesses that have achieved
sufficient scale to be profitable or profitable in the near future,
although not yet significant in cash generation for the Group
and likely to require funds to support new business growth.
These businesses are approximately 5 years or more into their
launch. Discovery Insure, excluding commercial insurance, and
Vitality Group have been disclosed as Emerging businesses.
Development and other segments include costs of start-up
businesses and expenses incurred to investigate, research and
develop new products and markets. Start-up costs include
costs in relation to, amongst others, Discovery Bank, the UK
investment business VitalityInvest, a commercial offering in
Discovery Insure, an Umbrella Fund offering in Discovery Invest
and the Vitality1 platform being a leading behavioural change
platform enabling shared-value insurance and financial services
products across the Discovery Group. Certain unallocated head
office costs are also included in this segment.
SIGNIFICANT TRANSACTIONS
AFFECTING THE CURRENT RESULTS
Operating in a COVID-19
environment
On 11 March 2020, the World Health Organisation declared
COVID-19 a global pandemic. COVID-19 has caused significant
disruption to lives and economies worldwide. In addition to its
health impacts, the pandemic has driven extreme market
volatility, as evidenced by interest rates and equity market

-- 30 of 56 --

29
and liquidity. The light scenario would result in a release of
provisions in future years.
In terms of mortality, the key areas of impact are Discovery Life
and VitalityLife. The modelling uses the United Kingdom’s
Imperial College studies as a basis for Infection Fatality Rates,
in combination with SEIR1 models based on local observed and
modelled infection reproductive rates to ascertain the duration
and impact of the pandemic on the Discovery Life and
VitalityLife insured populations. At 30 June 2020, the UK was at
a more advanced stage of the epidemic than SA, however both
markets are still subject to significant uncertainty at this stage
and therefore a prudent modelling approach has been assumed
in both cases.
Excess Health claims in the UK will arise due to the delay of
elective surgeries during the COVID-19 period as private
hospital capacity has been co-opted by the National Health
Service. These delayed effects have been modelled and
estimated as part of the central scenario and is reflected in the
profile of earnings recognised and the related unearned
premium reserves which were significantly altered due to
access to private health facilities. Furthermore, Discovery has
also modelled the claims arising from delayed COVID-19
admissions.
The economic effects were modelled to take account of the
economic stresses, particularly on policy lapses, in all of
Discovery’s long term insurance businesses under the range of
scenarios.
Materially volatile long-term interest rates
in SA and the UK which negatively
affected earnings
There has been substantial volatility in global markets and in
particular, material increases in long-term nominal and real
interest rates in SA and record low interest rates in the UK.
These result in materially different valuation rates that are used
to discount future cash flows and emerge as economic
assumption changes. For Discovery Life, this impact manifests
as a lower discounted value of future cash flows, even though
the actual cash flows themselves are not materially affected.
The SA yields have minimal impact on the actual cash flows
themselves, with no negative solvency and liquidity consequences
within Discovery Life.
The impact of the continued interest rate volatility in SA and the
UK has resulted in an increased negative effect of R5.7 billion
on reported profit from operations compared to what it would
have been at rates prevailing at the previous year-end.
The impact on the UK results were mitigated through the hedge
entered into in October 2019, as previously reported. Refer to
‘Derivative instruments – VitalityLife business’ for further detail.
Should the observed reference interest rates revert, these
valuation strains will reverse. Given there is no bearing on
operating performance, Discovery has excluded the effect, net
of tax, in the presentation of normalised earnings measures.
Although the allowance for the COVID-19 impact is an abnormal
provision for future impacts, it is not excluded in the
presentation of normalised headline earnings because it is
seen as part of the core operations and will impact future cash
flows.
Derivative instruments –
VitalityLife business
As highlighted above, interest rates in the UK have displayed
significant volatility and have generally been on a downward
trend in recent years. In the period under review, VitalityLife
implemented an interest rate risk mitigation strategy to protect
itself against further declines in interest rates by entering into
derivative contracts. This strategy ensures that the VitalityLife
business operates well within its pre-determined risk appetite.
The derivative instruments comprise of:
❚ 	Two interest rate swaps, with a nominal value of GBP
350 million (R7 505 million) and GBP 90 million (R1 930 million)
respectively. These interest rate swap derivatives swap
exposure to variable interest rates in return for a fixed
interest rate referenced to the 25-year UK swap rate as at 25
October 2019 (‘reference swap rate 1’) and 10 June 2020
(‘reference swap rate 2’) respectively. Both interest rate swap
derivatives are in place for an extended period of time; and
❚ 	Two put swap options (payer swaptions). Swaption one was
acquired at a premium of GBP 6.2 million (R133 million) and
was settled before year-end. Swaption two was acquired for
GBP 12.3 million (R264 million) and expires in May 2023.
These swaptions give Discovery the participation in the
benefit should interest rates rise by more than 0.45% above
reference rate 1 and 0.88% above reference rate 2.
1 The classical SEIR model determines the total number of people with a basic hypothesis that all individuals will have four roles, being Susceptible (S),
Exposed (E), Infectious (I) and recovered (R).

-- 31 of 56 --

30 Discovery Audited results for the year ended 30 June 2020
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2020
Due to the nature of the underlying exposures, the hedge accounting requirements of IFRS were not applicable. Therefore, these two
derivative instruments were classified at fair value with changes recognised in profit or loss throughout the term which may result in
volatility in the reported IFRS earnings of VitalityLife. As at 30 June 2020, the following mark-to-market positions were recorded:
Line item in financial statements 	June 2020
Statement of Financial Position
Interest rate swap valuation 	Financial assets: Derivative – financial instruments
at fair value through profit or loss 	GBP 44.3 million (R950 million)
Swaption valuation 	Financial assets: Derivative – financial instruments
at fair value through profit or loss 	GBP 0.1 million (R2 million)
Original premium 	GBP 18.5 million (R396 million)
Deferred payments 	(GBP 12.3 million (R264 million))
Fair value remeasurement 	(GBP 6.1 million) (R120 million))
Income Statement
Fair value remeasurement loss 	Net fair value gains/(losses) on financial assets
at fair value through profit or loss 	GBP 38.4 million (R758 million)
Transaction costs 	Marketing and administration expenses 	GBP 2.3 million (R45 million)
From an economic perspective, VitalityLife effectively fixed the reference swap rate as at 25 October 2019 (being 0.96%). In doing
so, VitalityLife limited its exposure to approximately GBP 43.7 million (R863 million) as a result of the valuation of specified future
policy obligations. This estimate excludes the cost of option premiums and ignores any potential basis risk.
Borrowings at amortised cost
R million 	Reference
June
2020
June
2019
Borrowings from Banks and listed debt 	15 456 	11 034
– United Kingdom borrowings 	i 	3 498 	1 612
– South African borrowings 	ii 	11 958 	9 422
Lease liabilities 	4 380 	3 648
– 1 Discovery Place 	3 370 	3 321
– Other lease liabilities 	iii 	1 010 	327
Total borrowings at amortised cost 	19 836 	14 682
i. 	United Kingdom borrowings
Discovery Finance Company Europe Limited, a subsidiary of Discovery Limited had GBP 90 million owing on an amortising
facility at 30 June 2019. A further GBP 10 million of this facility was repaid during the year. The remaining GBP 80 million was
refinanced into a new amortising facility in March 2020, for a further 40 months to 31 July 2023.
Discovery Finance Company Europe Limited also entered into a credit facility agreement totalling GBP 28 million on 17 April
2020. These facilities are short-term in nature and repayable on 17 April 2021.
Interest on the GBP 80 million loan is linked to the 3-month LIBOR plus a margin of 2.65% per annum and is payable quarterly
in arrears. The capital is repayable in bi-annual tranches of GBP 7.5 million commencing on 1 April 2021, with a final repayment
of GBP 42.5 million at maturity.
Interest on the GBP 28 million loan is fixed at 1% per annum and is payable quarterly in arrears.
The balance owing at 30 June 2020 for these facilities amounts to GBP 108 million (R2 321 million) and finance costs of
GBP 0.75 million (R15 million) in respect of these borrowings have been recognised in profit or loss.
In addition, Discovery Holdings Europe Limited, an ultimate subsidiary of Discovery Limited entered into another facility of
GBP 55 million during the year. GBP 40 million of this facility was drawn down at 30 June 2020. Interest on this facility is linked
to the 3-month LIBOR plus a margin of 2.29% per annum and is payable quarterly in arrears. The capital is repayable in full at
maturity on 31 July 2023.

-- 32 of 56 --

31
This facility had a provision which allowed the total amount to be extended by a further GBP 45 million to GBP 100 million on
the same terms. The provision was exercised on 22 June 2020. The balance owing at 30 June 2020 is GBP 55 million
(R1 177 million) and finance costs of GBP 0.35 million (R7 million) in respect of these borrowings have been recognised in profit
or loss.
ii. 	South African borrowings
R million 	Reference
June
2020
June
2019
Balance at beginning of the year 	9 422 	7 240
Issuance of listed debt 	i 	1 520 	700
Issuance of unlisted debt 	ii 	3 600 	–
Draw down on existing and new bank facilities 	iii 	2 000 	1 447
Repayment of borrowings 	(4 626) 	(30)
Accrued interest 	58 	68
– Finance costs capitalised to intangible assets 	– 	47
– Finance costs expensed to profit or loss 	976 	787
– Finance costs paid 	(918) 	(766)
Raising fees capitalised 	(16) 	(4)
Net foreign exchange differences 	– 	1
Balance at end of the year 	11 958 	9 422
Following the downgrade of the South African Government’s issuer rating to Ba1 from Baa3 on 27 March 2020, Moody’s
Investor Service downgraded Discovery Limited’s national scale rating from Aa3.za to A1.za and the global scale rating from
Ba1 to Ba2 on 1 April 2020, similar to the country outlook, the credit outlook assigned by Moody’s remain negative.
i 	In 2017, Discovery registered an unsecured R10 billion Domestic Medium Term Note (DMTN) programme. In terms of this
programme, Discovery had issued a cumulative amount of R2.2 billion in JSE Listed Notes to 30 June 2019. Discovery further
issued, via bond placements, 5-year and 7-year Floating Rate Notes of R1.2 billion and R300 million respectively on
26 November 2019, with coupon interest rates of 8.85% and 9.35% per annum respectively, fixed through interest rate
swaps. Interest is payable quarterly in arrears with capital repayable in full at maturity date.
ii During the current year, Discovery Limited refinanced 5-year bank facility loans totalling R3.6 billion entered into in 2016
for a further 3 and 5 years, through the issue of a series unlisted DMTN notes totalling R1.1 billion and R2.5 billion
ultimately maturing in March 2023 and February 2025, respectively. These unlisted notes have been structured through an
underwritten subscription agreement with a bank and guaranteed by Discovery Health and Discovery Vitality. Interest is
payable quarterly in arrears at fixed rates of 8.915% per annum and 9.615% per annum respectively, with capital repayable
in full at maturity date.
iii During the period:
– Discovery Central Services drew down on an unsecured revolving credit facilities of R500 million, interest rates between
6.7% and 7.94% per annum, which were repaid during the year.
– Discovery Bank entered into a 2 year revolving credit facility of R1 billion. The facility is structured with R500 million
guaranteed by Discovery Limited, Discovery Vitality and Discovery Health while the remaining R500 million is not
guaranteed. Interest on both facilities is linked to the 3-month JIBAR plus a margin of 1.25% per annum and 1.35% per
annum. Interest is payable quarterly in arrears and capital is repayable in full at maturity on 19 July 2021.
Finance costs of R976 million (2019: R832 million) in respect of South African borrowings and related hedges have been
recognised in profit or loss.
iii. Other lease liabilities
Refer to ‘New accounting standards’ for the impact of the first time adoption of IFRS 16 Leases, adopted by Discovery from
1 July 2019.

-- 33 of 56 --

32 Discovery Audited results for the year ended 30 June 2020
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2020
OTHER SIGNIFICANT ITEMS IN
THESE RESULTS
Increase in cash and cash
equivalents 2020 	2019
Unit-linked investment and
insurance contracts1 	2 502 	2 751
Shareholder cash 	15 407 	6 652
Balance at 30 June 	17 909 	9 403
1 Includes cash held within specific portfolios to match specific
insurance liabilities.
The shareholder Cash and cash equivalents position at 30 June
2020, increased by R8.8 billion when compared to 30 June 2019.
The increase can mainly be attributed to the following:
R billion 	Reference
Increase
in cash
position at
30 June 2020
Translation differences as a result
of depreciation of the rand 	1.3
Discovery Bank 	i 	2.0
VitalityLife 	ii 	4.7
Matured investments 	iii 	0.4
Other 	0.4
Total 	8.8
i. Discovery Bank
Discovery Bank raised wholesale deposits of R1.5 billion to fund
advances for the subsequently completed Platinum client
portfolio migration from FirstRand Bank, which took place in
July 2020. Liquid assets requirements of 7.5% of customer
deposits, together with liquidity buffer requirements, resulted
in approximately R500 million of cash to be held.
ii. VitalityLife
Per the reinsurance treaty entered into in respect of business
written on the Prudential license, a security deposit was
required to be placed by the reinsurer, to reduce counterparty
risk.
The contractual arrangement in respect of this business is
accounted for as a reinsurance contract under IFRS 4 and as a
result the 'deposit back' was disclosed as a reduction in the
negative reserve funding liability in previous periods. From the
prior financial year amounts received as 'deposit back' in
excess of the negative reserve funding was disclosed as part of
cash and cash equivalents and a corresponding liability has
been raised in Other Payables at amortised cost.
In addition, this book of business is also in a cash generating
position as no new business is being written. The increase in
cash on this book of business which includes the above
mentioned ‘deposit back’ was GBP 114 million (R2.4 billion) for
the year.
Significant gains on expired interest rate derivatives held resulted
in a further increase in cash of GBP 41 million (R880 million) for
the year. Collateral of GBP 45 million (R965 million) received on
interest rate derivative balances (as discussed under Derivative
instruments earlier) are also included in Cash and cash
equivalents with an opposite liability disclosed as part of Other
payables at amortised cost.
During the 2020 financial year, Discovery Holdings Europe
Limited, an ultimate subsidiary of Discovery Limited also drew
down GBP 55 million (R1.2 billion) of which GBP 20 million
(R420 million) has not been utilised at the end of June 2020.
Refer to Borrowings at amortised cost discussed earlier.
iii. Matured investments
The cash balance of the Group includes R370 million of
investments that matured on 30 June 2020. These were
reinvested the following day, which would then be disclosed as
Financial assets in the Statement of Financial Position.
Deferred tax
With the promulgation of the South African Insurance Act 18 of
2017, the new ‘adjusted IFRS’ tax basis has been effective since
1 July 2018 for Discovery Life. Deferred tax has been provided for
on the difference between the IFRS and tax liabilities to the extent
that timing differences arise. A deferred tax liability of R8 681 million
relates to assets and liabilities arising from insurance contracts.
Consolidation of Discovery Unit
Trusts
The Discovery Unit Trusts are consolidated into Discovery’s
results for accounting purposes, which results in the recognition
of the underlying assets and liabilities of each of the funds.
Assets and liabilities of the Discovery Unit Trusts increased by
R379 million respectively, compared to the prior financial year
with movements in the following line items on the Group’s
Statement of Financial Position:
Changes in assets
❚ 	Investments at fair value through profit or loss increased by
R586 million.
❚ 	Cash and cash equivalents decreased by R732 million.
❚ 	Insurance receivables, contract receivables and other non-
financial receivables increased by R543 million.
❚ 	Other assets decreased by R18 million.

-- 34 of 56 --

33
Changes in liabilities
❚ 	Investment contracts at fair value through profit or loss
increased by R333 million.
❚ 	Other liabilities increased by R46 million.
As these policies are linked, the consolidation of the Discovery
Unit Trusts has no impact on the net asset value for
shareholders.
There are significant trade volumes in the underlying funds of
Discovery Unit Trusts. The cash flow impact of the movement in
policyholder investments for the period is included in the
following line items on the Group’s Statement of cash flows:
❚ 	Purchase of investments held to back policyholder liabilities
includes cash outflows of R15.4 billion.
❚ 	Proceeds from the disposal of investments held to back
policyholder liabilities includes cash inflows of R14.3 billion.
Material transactions with related
parties
Discovery Health Medical Scheme (DHMS)
Discovery Health administers DHMS and provides managed
care services for which it charges an administration fee and a
managed healthcare fee respectively. These fees are
determined on an annual basis and approved by the trustees
of DHMS. The fees totalled R6 190 million for the year ended
30 June 2020 (2019: R5 853million). Discovery offers the
members of DHMS access to the Vitality programme.
Equity issued to related parties
Per Discovery Limited’s long-term incentive plan which was
approved by shareholders at the annual general meeting held
on 28 November 2019, the awards accepted by executive
directors and prescribed officers amount to a deemed
transaction value of R29 million and R28 million respectively.
These will vest from between the 3rd and 5th anniversary of
the awards (between 1 October 2022 and 1 October 2024),
provided the necessary performance and vesting criteria have
been achieved.
SHAREHOLDER INFORMATION
Directorate
Changes to the Board of Discovery Limited from 1 July 2019 to
the date of this announcement are as follows:
❚ 	Following a period of medical leave, Mr H Mayers, moved
from an executive director role to a non-executive director
role effective 28 November 2019.
❚ 	Mr D Macready has been appointed as an independent non-
executive director with effect from 3 February 2020.
❚ 	Mr L Owen, an independent non-executive director, retired,
effective 14 February 2020.
Changes in executive director responsibilities from 1 July 2019
to the date of this announcement are as follows:
❚ 	Mr NS Koopowitz, Chief Executive Officer (CEO) of
VitalityHealth, became CEO of the Vitality UK Group, effective
28 November 2019. This will create a single point of
accountability for delivery of the composite model, as well
as a number of Group functions that span across both
VitalityHealth and VitalityLife in key areas.
❚ 	Mr HD Kallner, CEO of Discovery Life, assumed the role of
CEO of Discovery’s South African operations effective
29 January 2020. In the role, Mr Kallner will lead the
composite strategy for Health, Life, Invest, Insure, and
Vitality entities, and will oversee their integration with Vitality
and Discovery Bank. Mr Kallner will continue to chair the SA
Executive Committee, as the core governance forum of the SA
composite.
Dividend and capital
Interim dividends paid in respect of the
2020 financial year
The following interim dividends were paid during the current
period:
❚ 	B preference share dividend of 505.41097 cents per share
(404.32878 cents net of dividend withholding tax), paid on
16 March 2020.
❚ 	Ordinary share dividend of 101 cents per share (80.8 cents
net of dividend withholding tax), paid on 23 March 2020.

-- 35 of 56 --

34 Discovery Audited results for the year ended 30 June 2020
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2020
Final dividend declaration in respect of the
2020 financial year
B preference share cash dividend declaration:
On 7 September 2020, the directors declared a final gross cash
dividend of 433.21918 cents (346.57534 cents net of dividend
withholding tax) per B preference share for the period
1 January 2020 to 30 June 2020, payable from the income
reserves of the Company. A dividend withholding tax of 20%
will be applicable to all shareholders who are not exempt.
The issued preference share capital at the declaration date is
8 million B preference shares.
The salient dates for the dividend will be as follows:
Last day of trade to receive a
dividend 	Monday, 21 September 2020
Shares commence trading
“ex” dividend 	Tuesday, 22 September 2020
Record date 	Friday, 25 September 2020
Payment date 	Monday, 28 September 2020
B Preference share certificates may not be dematerialised or
rematerialised between Tuesday, 22 September 2020 and
Friday, 25 September 2020.
Ordinary share cash dividend declaration:
Due to the uncertain and potentially volatile economic
environment caused by the COVID-19 pandemic, Discovery will
not be recommending the payment of ordinary dividends. The
reintroduction of dividends will be considered when appropriate.
Capital
For Group subsidiaries that operate in the insurance and
financial services sectors, the relevant regulator specifies the
minimum amount and type of capital that must be held by each
of the subsidiaries in addition to their insurance liabilities. The
minimum required capital must be maintained at all times
throughout the period.
With effect from 1 July 2018, the Insurance Act 18 of 2017
(Insurance Act), and the related Prudential Standards were
implemented in South Africa. Discovery Life and Discovery
Insure are regulated under the Insurance Act, while Vitality
Health and VitalityLife are regulated under the European
Solvency II regulatory regime, which was implemented from
1 January 2016.
The table below summarises the capital requirements on the
statutory basis, across the Group subsidiaries, and the actual
solvency capital held in relation to this requirement.
June 2020 	June 2019
Statutory capital requirements 	Cover 	Statutory capital requirements 	Cover
Discovery Life 	R14 835 million 	1.8 times 	R17 396 million 	1.6 times
Discovery Insure 	R885 million 	1.8 times 	R789 million 	1.7 times
Vitality Health 	GBP 102.3 million (R2 194 million) 	1.7 times 	GBP 97 million (R1 777 million) 	1.4 times
VitalityLife Limited 	GBP 228.3 million (R4 896 million) 	2.0 times 	GBP 208 million (R3 810 million) 	1.5 times

-- 36 of 56 --

35
ACCOUNTING POLICIES
New accounting standards
IFRS 16 Leases
Background
IFRS 16 replaces IAS 17 Leases, as well as the related
interpretations. The core principle of IFRS 16 is that the
lessee should recognise all rights and obligations arising
from leasing arrangements in its Statement of Financial
Position. The most significant change to Discovery
pertains to the accounting treatment for those leases that
were classified as operating leases from Discovery’s
perspective as the lessee.
IFRS 16 eliminates the classification of leases for lessees
as either operating or finance leases as per IAS 17.
Instead, IFRS 16 introduces a single lessee accounting
model, where a right of use (ROU) asset together with a
lease liability for the future payments is recognised for all
leases with a term of more than 12 months, unless the
underlying asset is of a low value. Where Discovery is the
lessee, it has elected, in accordance with IFRS 16, not to
apply the lessee accounting model where the lease is a
short-term lease. Short-term leases have a lease term of
12 months or less and does not include a renewal option.
The rental payments for short-term leases are expensed
on a straight-line basis over the lease term.
IFRS 16 does not introduce significant changes for lessors,
or to those leases previously classified as finance leases
from the lessee’s perspective, and as a result the
accounting policies for these transactions had no material
change.
Adoption and transition
On adoption of IFRS 16, Discovery applied the modified
retrospective approach to transition on 1 July 2019. This
approach requires the cumulative effect of initially
applying IFRS 16 as an adjustment to the opening reserves
at 1 July 2019. As required by IFRS 16, Discovery did not
restate its comparative financial results. Accordingly:
❚ 	Discovery’s previously reported financial results up to
30 June 2019 are presented in accordance with the
requirements of IAS 17; and
❚ 	From 1 July 2019 Discovery’s financial results are
presented in terms of IFRS 16.
On adoption of IFRS 16, Discovery recognised lease
liabilities in relation to leases which had previously been
classified as operating leases under the principles of IAS 17. These
liabilities were measured at the present value of the remaining
lease payments, discounted using the lessee’s incremental
borrowing rate as at 1 July 2019. This incremental borrowing rate
was calculated for each legal entity within the Group that entered
into lease arrangements. The incremental borrowing rate
considers a base interest rate reflective of the jurisdiction in which
the legal entity operates (South Africa, United Kingdom and
United States of America), the term of the lease arrangement and
the nature of the assets.
ROU assets were measured retrospectively at the amount equal
to the lease liability at commencement of the lease, using the
discount rate as determined on 1 July 2019 for the lease liability,
and depreciated from commencement date up until 30 June 2019.
The resulting difference between the lease liability and the ROU
asset as at 1 July 2019 is recognised as an adjustment to the
opening retained earnings. In addition, any previously recognised
rights (e.g. prepaid rentals) or obligations (e.g. straight-line
accruals) are also derecognised as adjustments to the opening
retained earnings on 1 July 2019.
Practical expedients applied
In applying IFRS 16 for the first time, Discovery used the following
practical expedients permitted by IFRS 16:
❚ 	accounting for leases with a remaining lease term of less than
12 months as at 1 July 2019, as short-term leases, provided
there was no option to extend the term. For short-term rentals,
the lessee recognised the payments as an expense on a
straight-line basis;
❚ 	the use of a single discount rate for a specified portfolio of
leases that have reasonably similar characteristics;
❚ 	the exclusion of initial direct costs for the measurement of the
ROU asset at the date of initial application; and
❚ 	the use of hindsight in determining the lease term where the
contract contains options to extend or terminate the lease.
Identifying leases, low value assets and leasing
activities
Effective 1 July 2019, all leases, which either had a term not less
than 12 months or not deemed a low value asset, were recognised
as a ROU asset and a corresponding lease liability.
Discovery leases the following assets with a range of lease terms:
❚ 	Large offices 	5 – 15 years
❚ 	Small offices/Franchise offices (SA only) 	1 – 3 years
❚ 	Computer equipment (e.g. servers) (SA only) 	3 – 4 years
❚ 	Motor vehicles (UK only) 	3 years

-- 37 of 56 --

36 Discovery Audited results for the year ended 30 June 2020
REVIEW OF GROUP RESULTS continued
for the year ended 30 June 2020
Leases of low value assets relate to those categories of assets
which at inception of the lease typically have a value, if bought
new, of no more than approximately R70 000. For Discovery,
these categories include computer equipment such as
desktops, laptops, monitors and related IT peripherals.
Contracts where the service provider has a substantive right to
substitute the asset for an alternative asset during the lease
term is not regarded as a lease, but instead a service contract.
Accordingly, these contracts are not accounted for in
accordance with IFRS 16. For Discovery, such contracts include
items such as vending machines.
Extension/termination options
Extension and termination options are included in a number of the building leases across the Group. These terms are used to
maximise operational flexibility in terms of managing contracts. In determining the lease term, management considers all facts and
circumstances that create an economic incentive to exercise an extension option, or not exercise a termination option. Extension
options (or periods after termination options) are considered in the lease term when there is reasonable certainty that those
options will be exercised.
Effect of changes in IFRS 16 on date of initial application
at 1 July 2019
Group
30 June
2019 	Group
Previously 	1 July
reported 	IFRS 16 	2019
R million 	Audited 	Adjustments 	Restated
Assets
Property and equipment1, 3 	4 212 	638 	4 850
Total impact on assets 	638
Equity
Retained earnings3 	31 710 	(41) 	31 669
Liabilities
Financial liabilities
Borrowings at amortised cost 2, 3 	14 682 	748 	15 430
– Other payables at amortised cost 	10 262 	(63) 	10 199
– Deferred income tax liabilities 	8 697 	(6) 	8 691
Total impact on equity and liabilities 	638
1, 2 The increase in Property and equipment and Borrowings at amortised cost related to:
R million
Property
and
equipment
Borrowings
at amortised
cost
Land and buildings3 	573 	681
Computer equipment and operating systems 	64 	66
Motor vehicles 	1 	1
638 	748
3 	In the finalisation of the results for the year ended 30 June 2020, Discovery identified that in its interim financial results, it incorrectly treated a
reimbursement of fitout costs from the lessor, in the measurement of its Buildings R2U asset. Discovery has corrected its calculation, and the
values above are after its correction. Accordingly, the values in the table above are R29 million less for its R2U asset, R1 million less for Borrowing
at amortised cost and R28 million more for Retained earnings than those values included in the interim financial results. The change has no
impact on earnings during the period.
4 	The ranges of incremental borrowing rates applied on transition was 8.02%-9.9% in South Africa, 1.92%-4.43% in the UK and 7.25% within the US.

-- 38 of 56 --

37
Material events after reporting
date
Subsequent to year-end, Discovery Bank successfully migrated
the DiscoveryCard Platinum client portfolio, comprising of
62 512 customers from the FNB platform onto its own platform.
The transfer was funded by various institutional deposits
amounting to R1.3 billion.
Basis of preparation
The Group’s summary consolidated financial statements are
prepared in accordance with the requirements of the JSE
Listings Requirements, and the requirements of the Companies
Act of South Africa applicable to summary financial statements.
The Listings Requirements require summarised reports to be
prepared in accordance with the framework concepts and the
measurement and recognition requirements of International
Financial Reporting Standards (IFRS) and the SAICA Financial
Reporting Guides as issued by the Accounting Practices
Committee and Financial Pronouncements as issued by the
Financial Reporting Standards Council and to also, as a
minimum, contain the information required by IAS 34 Interim
Financial Reporting.
The accounting policies applied in the preparation of the
consolidated financial statements from which the summary
consolidated financial statements were derived are in terms of
International Financial Reporting Standards and are consistent
with those accounting policies applied in the preparation of
the previous consolidated annual financial statements, except
for the new accounting standards as set out earlier in this
report.
Audit
The summary consolidated financial statements are extracted
from audited information, but are not audited. The annual
financial statements were audited by PricewaterhouseCoopers
Inc., who expressed an unmodified opinion thereon.
The audited annual financial statements and the auditor’s
report thereon are available for inspection at the Company’s
registered office, together with the financial statements
identified in the respective auditor’s reports.
The directors of Discovery take full responsibility for the
preparation of this report and that the financial information
has been correctly extracted from the underlying annual
financial statements.

-- 39 of 56 --

38 Discovery Audited results for the year ended 30 June 2020
EMBEDDED VALUE STATEMENT
for the year ended 30 June 2020
The embedded value of Discovery consists of the following components:
❚ 	the adjusted net worth attributed to the business at the valuation date;
❚ 	plus: the present value of expected future shareholder cash flows from the in-force covered business;
❚ 	less: the cost of required capital.
The present value of future shareholder cash flows from the in-force covered business is calculated as the value of projected future
after-tax shareholder cash flows of the business in-force at the valuation date, discounted at the risk discount rate.
The required capital are the assets attributed to the covered business above the amount required to back covered business
liabilities, whose distribution to shareholders is restricted as they are allocated to cover regulatory and internal capital requirements.
The value of new business is the present value, at the point of sale, of the projected future after-tax shareholder cash flows of the
new business written by Discovery, discounted at the risk discount rate, less an allowance for the reserving strain, initial expenses
and cost of required capital. The value of new business is calculated using the current reporting date assumptions.
The embedded value includes the insurance and administration profits of the covered business in the Discovery Limited group.
Covered business includes business written in South Africa through Discovery Life (“Life”), Discovery Invest (“Invest”), Discovery
Health (“Health”) and Discovery Vitality (“Vitality”), and in the United Kingdom through VitalityLife and VitalityHealth. For Vitality
Group, Ping An Health, MyOwn Health, Discovery Insure, Discovery Bank and VitalityInvest, no published value has been placed on
the current in-force business as the businesses have not yet reached suitable scale with predictable experience.
In August 2011, Discovery raised R800 million through the issue of non-cumulative, non-participating, non-convertible preference
shares. For embedded value purposes this capital, net of share issue expenses, has been excluded from the adjusted net worth.
The embedded value at 30 June 2020 has been materially impacted by the COVID-19 global pandemic, resulting in both experience
variances and short term provisions for adverse future experience. Refer to Tables 5 and 6 for details.
Following the finalisation of the agreement with Prudential in February 2020 to delay the transfer of the VitalityLife business on the
Prudential licence to the VitalityLife Limited licence (“the Part VII transfer”, which is subject to the relevant legal and regulatory
approvals), an adjustment has been made in the embedded value to allow for the cost of this arrangement and the cost of the
required capital for VitalityLife.
The 30 June 2020 embedded value results and disclosures were subjected to an external review.

-- 40 of 56 --

39
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2020
TABLE 1: GROUP EMBEDDED VALUE
R million
30 June
2020
30 June
2019
%
change
Shareholders’ funds 	44 553 	43 083 	3
Adjustment to shareholders’ funds from published basis1 	(32 080) 	(32 690)
Adjusted net worth2 	12 473 	10 393
Value of in-force covered business before cost of required capital 	64 305 	63 862
Cost of required capital 	(5 944) 	(3 038)
Discovery Limited embedded value 	70 834 	71 217 	(1)
Number of shares (millions) 	656.6 	656.6
Embedded value per share 	R107.88 	R108.46 	(1)
Diluted number of shares (millions) 	657.6 	657.6
Diluted embedded value per share3 	R107.71 	R108.30 	(1)
1 A breakdown of the adjustment to shareholders’ funds is shown in the table below. Note that where relevant, adjustments have been converted
using the closing exchange rate of R21.44/GBP (June 2019: R17.98/GBP)
R million
30 June
2020
30 June
2019
Life and Invest net assets under insurance contracts 	(18 564) 	(20 764)
VitalityLife Limited and Discovery funded VitalityLife business on the Prudential licence net assets under
insurance contracts 	(6 320) 	(5 812)
Vitality+ealth ȴnancial reinsurance asset 	(3 078) 	(2 315)
VitalityHealth and VitalityHealth Insurance Limited deferred acquisition costs (net of deferred tax) 	(467) 	(382)
VitalityLife receivable relating to the 8nemployment &over beneȴt net of deferred tax 	(21) 	(19)
Goodwill relating to the acquisition of Standard Life Healthcare and the Prudential joint venture 	(2 653) 	(2 225)
Intangible assets (net of deferred tax) in covered businesses 	(945) 	(800)
Net preference share capital 	(779) 	(779)
Reversal of 1 Discovery Place IAS 17 ȴnancial lease accounting 	747 	406
Equity settled share based payment provision adjustment 	0 	–
(32 080) 	(32 690)
The “equity settled share based payment provision adjustment” adjustment reflects the difference between the provision in the IFRS equity and the
marNtomarNet value of the equity settled share based payments. At 30 June 2020 this adjustment is R0.33 million.
2 	The following table sets out the capital position of the covered businesses with the required capital on a consistent basis to that used in the
embedded value:

-- 41 of 56 --

40 Discovery Audited results for the year ended 30 June 2020
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2020
R million
30 June
2020
30 June
2019
Shareholders’ funds 	44 553 	43 083
Adjustment to shareholders' funds 	(32 080) 	(32 690)
Adjusted net worth 	12 473 	10 393
Excess of available capital over adjusted net worth 	23 231 	26 773
Available capital 	35 704 	37 166
Required capital 	29 932 	30 987
Excess available capital 	5 772 	6 179
The excess of available capital over adjusted net worth reflects the difference between the adjusted net worth and the available capital. This
includes:
◼ The net preference share capital of R779 million which is included as available capital.
◼ The difference between VitalityLife Limited’s Solvency II Pillar 1 Own Funds and its adjusted net worth and adds back the negative reserves eliminated
on the Discovery funded VitalityLife business on the Prudential licence.
◼ The difference between Life and Invest’s Pillar 1 Own Funds and its adjusted net worth.
The required capital at June 2020 for Life and Invest is R18 544 million (June 2019: R21 724 million), for Health and Vitality is R935 million (June
2019: R909 million), for VitalityHealth is R2 963 million (June 2019: R2 350 million) and for VitalityLife is R7 490 million (June 2019: R6 004 million).
For Life and Invest, the required capital was set equal to 1.25 times the SAM Pillar 1 Solvency Capital Requirement. For Health and Vitality, the
required capital was set equal to two times the monthly renewal expense and Vitality benefit cost. For VitalityHealth, the required capital amount
was set equal to 1.35 times the Solvency II Pillar 1 Solvency Capital Requirement. For the VitalityLife business on the Prudential licence, the required
capital was set equal to the UK Solvency I long term insurance capital requirement as per the agreement with Prudential up to the Part VII transfer,
thereafter it is set equal to 1.4 times the Solvency II Pillar 1 Solvency Capital Requirement. For the business sold on the VitalityLife Limited licence,
the required capital was set equal to 1.4 times the Solvency II Pillar 1 Solvency Capital Requirement.
3 The diluted embedded value per share adjusts for treasury shares held in the Discovery BEE Share Trust where the impact is dilutive.

-- 42 of 56 --

41
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2020
TABLE 2: VALUE OF IN-FORCE COVERED BUSINESS
R million
Value before
cost of
required
capital
Cost of
required
capital
Value after
cost of
required
capital
at 30 June 2020
Health and Vitality 	22 321 	(419) 	21 902
Life and Invest1 	23 752 	(1 244) 	22 508
VitalityHealth2 	10 077 	(495) 	9 582
VitalityLife 2, 3 	8 155 	(3 786) 	4 369
Total 	64 305 	(5 944) 	58 361
at 30 June 2019
Health and Vitality 	21 465 	(394) 	21 071
Life and Invest1 	27 277 	(1 177) 	26 100
VitalityHealth2 	7 840 	(378) 	7 462
VitalityLife2 	7 280 	(1 089) 	6 191
Total 	63 862 	(3 038) 	60 824
1 Included in the Life and Invest value of inforce covered business is R1 440 million (June 2019: R1 429 million) in respect of investment management
services provided on off balance sheet investment business. The net assets of the investment service provider are included in the adjusted net
worth.
2 The value of in-force has been converted using the closing exchange rate of R21.44/GBP (June 2019: R17.98/GBP).
3 The increase over the financial year in the cost of required capital for VitalityLife is explained under Table 6.
TABLE 3: GROUP EMBEDDED VALUE EARNINGS
Twelve months ended
R million
30 June
2020
30 June
2019
Embedded value at end of period 	70 834 	71 217
Less: Embedded value at beginning of period 	(71 217) 	(65 624)
Increase in embedded value 	(383) 	5 593
Net change in capital1 	– 	(1 839)
Dividends paid 	1 494 	1 481
Transfer to hedging reserve 	430 	175
Employee share option schemes 	(164) 	(33)
Increase in treasury shares 	4 	5
Acquisition of subsidiaries with non-controlling interest2 	(6) 	–
Change in ownership3 	– 	1 104
IFRS transitional arrangements4 	41 	73
Embedded value earnings 	1 416 	6 559
Annualised return on opening embedded value 	2.0% 	10.0%
1 The net change in capital reflects share issues (net of costs) and an increase (decrease) in treasury shares in the period.
2 This balance arose from the acquisition of the MS2 *roup in Health.
3 The change in ownership reflects the acquisition of the remaining 48.87% interest in Discovery Bank from FRIHL, being the non-controlling
interest.
4 The IFRS transitional arrangements reflects the retrospective adjustments arising from the adoption of IFRS 9 and IFRS 15 to the opening balances
at 1 July 2018.

-- 43 of 56 --

42 Discovery Audited results for the year ended 30 June 2020
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2020
TABLE 4: COMPONENTS OF GROUP EMBEDDED VALUE EARNINGS
Twelve months ended 30 June 2020
Year ended
30 June 2019
R million
Net
worth
Cost of
required
capital
Value of
in-force
covered
business
Embedded
value
Embedded
value
Total profit from new business (at point of
sale) 	(4 614) 	(271) 	6 807 	1 922 	2 622
Profit from existing business
◼ Expected return 	6 125 	72 	191 	6 388 	6 000
◼ Change in methodology and assumptions1 	2 871 	(2 118) 	(9 512) 	(8 759) 	(1 930)
◼ Experience variances 	250 	(107) 	(10) 	133 	19
Impairment, amortisation and fair value
adjustment2 	(16) 	– 	– 	(16) 	(37)
Increase in goodwill and intangibles 	(313) 	– 	– 	(313) 	(244)
Other initiative costs3 	(93) 	– 	44 	(49) 	914
Non-recurring expenses 	(181) 	– 	– 	(181) 	(3)
Acquisition costs4 	(7) 	– 	(5) 	(12) 	(39)
Finance costs 	(1 368) 	– 	– 	(1 368) 	(1 060)
Foreign exchange rate movements 	899 	(482) 	2 927 	3 344 	(178)
Other5 	18 	– 	1 	19 	76
Return on shareholders’ funds6 	308 	– 	– 	308 	419
Embedded value earnings 	3 879 	(2 906) 	443 	1 416 	6 559
1 The changes in methodology and assumptions will vary over time to reflect adjustments to the model and assumptions as a result of changes to
the operating and economic environment. The current period’s changes are described in detail in Table 6 below (for previous periods refer to
previous embedded value statements).
2 This item reflects the amortisation of the intangible assets reflecting the banking costs, the PrimeMed acquisition and capital expenditure in
VitalityInvest and Discovery Group Europe Limited.
3 This item includes the profits of non–covered businesses (including Discovery Insure, Vitality Group and Ping An Health) and costs of start–up
businesses (including Discovery Bank, VitalityInvest, a commercial offering in Discovery Insure, and an Umbrella Fund offering in Invest). Head
office costs which relate to non–covered business are also included in this item.
4 Acquisition costs relate to commission paid on the Life business and expenses incurred in writing Health and Vitality business that has been written
over the period but will only be activated and on risk after the valuation date. These policies are not included in the embedded value or the value
of new business and therefore the costs are not deducted from the value of new business.
5 This item includes, among other items, the tax benefits or losses that will emerge as the VitalityHealth DAC and intangible software assets amortise
or increase.
6 The return on shareholders’ funds is shown net of tax and management charges.

-- 44 of 56 --

43
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2020
TABLE 5: EXPERIENCE VARIANCES
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force 	Total
Renewal expenses 	74 	– 	3 	(2) 	(43) 	– 	10 	– 	42
Lapses and surrenders1 	(10) 	(298) 	88 	23 	– 	295 	(99) 	(147) 	(148)
Mortality and morbidity2 	– 	– 	147 	(1) 	(151) 	– 	(103) 	– 	(108)
Policy alterations3 	– 	40 	(516) 	174 	– 	– 	(9) 	(73) 	(384)
Premium and fee income 	127 	– 	(23) 	106 	69 	– 	(10) 	(51) 	218
Economic4 	19 	335 	(499) 	(557) 	– 	– 	– 	– 	(702)
Commission 	– 	– 	– 	– 	(27) 	– 	– 	– 	(27)
Tax5 	90 	– 	603 	(566) 	170 	– 	55 	– 	352
Reinsurance 	– 	– 	– 	– 	(2) 	– 	49 	(31) 	16
Maintain modelling term6 	– 	369 	– 	189 	– 	66 	– 	– 	624
Vitality benefits 	(27) 	– 	– 	– 	– 	– 	65 	– 	38
Other 	(2) 	2 	(26) 	61 	188 	– 	40 	(51) 	212
Total 	271 	448 	(223) 	(573) 	204 	361 	(2) 	(353) 	133
1 For Health and Vitality, the lapse and surrender experience variance relates to lower than expected replacement of exiting members in compulsory
membership schemes. For VitalityLife, the experience variance relates largely to adverse lapse experience on the term indexed optimiser product.
2 The mortality and morbidity experience for VitalityHealth includes a premium deferral provision for nonȂC2VIDȂ19 claims delayed due to private
hospital utilisation by the National Health Service during the pandemic.
3 The policy alterations experience for Life and Invest arises largely due to servicing and fund switches.
4 For Health and Vitality, the economic experience variance relates to the impact on administration and managed care fees of in–period inflation
being higher than that assumed. The experience for Life and Invest arises largely due to lower than expected linked asset growth for the period
under review.
5 The tax variance for Life and Invest arises due to a movement in the deferred tax asset which delays the payment of tax.
6 The projection term for Health and Vitality, Life and VitalityHealth at 30 June 2020 has not been changed from that used in the 30 June 2019
embedded value calculation. Therefore, an experience variance arises because the total term of the in–force covered business is effectively
increased by twelve months.

-- 45 of 56 --

44 Discovery Audited results for the year ended 30 June 2020
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2020
TABLE 6: METHODOLOGY AND ASSUMPTION CHANGES
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force 	Total
Modelling changes1 	– 	– 	(99) 	116 	– 	– 	(6) 	(849) 	(838)
Expenses2 	– 	(239) 	(9) 	(51) 	– 	– 	17 	(374) 	(656)
Lapses3 	– 	(394) 	106 	(936) 	– 	– 	24 	(404) 	(1 604)
Mortality and morbidity4 	– 	– 	– 	(844) 	– 	– 	(107) 	(165) 	(1 116)
Benefit changes 	– 	(25) 	– 	– 	– 	– 	– 	– 	(25)
Tax5 	– 	– 	– 	– 	– 	(187) 	– 	18 	(169)
Economic assumptions 6 	– 	(805) 	(40) 	(2 716) 	– 	299 	(397) 	(1 136) 	(4 795)
Premium and fee income7 	24 	545 	– 	– 	– 	– 	(40) 	(115) 	414
Reinsurance and financing8 	– 	– 	1 412 	(1 490) 	– 	(26) 	– 	– 	(104)
Other 9 	– 	– 	1 843 	(1 486) 	– 	– 	143 	(366) 	134
Total 	24 	(918) 	3 213 	(7 407) 	– 	86 	(366) 	(3 391) 	(8 759)
1 For VitalityLife, the cost of required capital following the Part VII transfer has been updated following the February 2020 agreement with
Prudential. This cost is sensitive to the economic conditions and the business mix at the time of the Part VII transfer. This impact is partially offset
by a methodology change in the calculation of the lapse risk component of the required capital and a change in the risk–free rate to be set with
reference to UK swap rates rather than the IFRS interest rate.
2 For VitalityLife, the value of in–force includes the fees payable to Prudential for the delay of the Part VII transfer.
3 The lapse assumption includes the impact of a short term stress to lapse assumptions in anticipation of adverse economic conditions over the
next two years.
4 For Life and VitalityLife, the mortality and morbidity assumption change relates to the increased provision for C2VIDȂ19 related claims.
5 For VitalityHealth the tax relates to the UK future tax rate changing from 17% to 19%.
6 For Life, Invest, Health and Vitality the economic assumptions item relates to the impact of updating the assumptions relative to the Johannesburg
Stock Exchange nominal and real yield risk–free curves at 30 June 2020. For VitalityHealth the item relates to the impact of changing the risk
discount rate. For VitalityLife the item relates to the impact of updating the assumptions relative to the Solvency II yield curves and the IFRS interest
rates, offset by a gain in the interest rate hedge.
7 For Health and Vitality, the premium and fee income item relates to an update of the contractual administration and managed care fees charged
for DHMS.
8 For Life, the reinsurance and financing item primarily relates to the impact of financing arrangements.
9 For VitalityLife, the other item relates to the margin reset to offset experience variances, as per the accounting policy, as well as an adjustment in
the value of in-force for the market value of the swaption as at 30 June 2020. For Life the other item relates to the change in the matching strategy
for long-term claims reserves.

-- 46 of 56 --

45
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2020
TABLE 7: EMBEDDED VALUE OF NEW BUSINESS
Twelve months ended
R million
30 June
2020
30 June
2019
%
change
Health and Vitality
Present value of future profits from new business (at point of sale) 	910 	832
Cost of required capital 	(27) 	(27)
Present value of future profits from new business (at point of sale) after cost of
required capital 	883 	805 	10
New business annualised premium income1 	3 972 	3 716 	7
Life and Invest
Present value of future profits from new business (at point of sale)2 	668 	1 242
Cost of required capital 	(82) 	(82)
Present value of future profits from new business (at point of sale) after cost of
required capital 	586 	1 160 	(49)
New business annualised premium income3 	2 886 	2 897 	(0)
Annualised profit margin4 	2.5% 	4.6%
Annualised profit margin excluding Invest business 	5.8% 	10.2%
VitalityHealth5
Present value of future profits from new business (at point of sale) 	262 	330
Cost of required capital 	(56) 	(59)
Present value of future profits from new business (at point of sale) after cost of
required capital 	206 	271 	(24)
New business annualised premium income (Rand)6 	1 308 	1 294 	1
Annualised profit margin4 	2.5% 	3.2%
VitalityLife7
Present value of future profits from new business (at point of sale) 	353 	520
Cost of required capital 	(106) 	(134)
Present value of future profits from new business (at point of sale) after cost
of required capital 	247 	386 	(36)
New business annualised premium income (Rand) 	956 	995 	(4)
Annualised profit margin4 	3.2% 	5.0%

-- 47 of 56 --

46 Discovery Audited results for the year ended 30 June 2020
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2020
1 Health new business annualised premium income is the gross contribution to the medical schemes. The new business annualised premium income
shown above excludes premiums in respect of members who join an existing employer where the member has no choice of medical scheme, as
well as premiums in respect of new business written during the period but only activated after 30 June 2020.
The total Health and Vitality new business annualised premium income written over the period was R6 146 million (June 2019: R6 831 million).
2 Included in the Life and Invest embedded value of new business is R29 million (June 2019: R70 million) in respect of investment management
services provided on off balance sheet investment business.
Risk business written prior to the valuation date allows certain Invest business to be written at financially advantageous terms, the impact of which
has been recognised in the value of new business.
3 Life new business is defined as Life policies to which Life became contractually bound during the reporting period, including policies whose first
premium is due after the valuation date. Invest new business is defined as business where at least one premium has been received and which has
not been refunded after receipt. Invest new business also includes Discovery Retirement 2ptimiser policies to which Life and Invest became
contractually bound during the reporting period, including policies whose first premium is due after the valuation date.
The new business annualised premium income of R2 886 million (June 2019: R2 897 million) (single premium APE: R1 453 million (June 2019: R1
321 million)) shown above excludes automatic premium increases and servicing increases in respect of existing business. The total new business
annualised premium income written over the period, including automatic premium increases of R1 496 million (June 2019: R1 370 million) and
servicing increases of R576 million (June 2019: R648 million), was R4 958 million (June 2019: R4 915 million) (single premium APE: R1 507 million
(June 2019: R1 382 million)). Single premium business is included at 10 of the value of the single premium.
Policy alterations and internal replacement policies, including Discovery Retirement 2ptimisers added to existing Life Plans, are shown in Table 5
as experience variances and not included as new business. Term extensions on existing contracts are not included as new business.
4 The annualised profit margin is the value of new business expressed as a percentage of the present value of future premiums.
5 The VitalityHealth value of new business is calculated as the value at point of sale of the new business written premium in–force at the valuation
date multiplied by the Margin multiplied by the Annuity Factor less the new business cash flows from point of sale to the valuation date. The
assumptions for the Margin and Annuity Factor are shown in Table 8.
6 VitalityHealth new business is defined as individuals and employer groups which incepted during the reporting period. The new business
annualised premium income shown above has been adjusted to exclude premiums in respect of members who join an existing employer group
after the first month, as well as premiums in respect of new business written during the period but only activated after 30 June 2020.
7 VitalityLife new business is defined as policies to which VitalityLife became contractually bound during the reporting period, including policies
whose first premium is due after the valuation date.

-- 48 of 56 --

47
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2020
BASIS OF PREPARATION
TABLE 8: EMBEDDED VALUE ECONOMIC ASSUMPTIONS
30 June
2020
30 June
2019
Beta coefficient 	0.75 	0.75
Equity risk premium (%) 	3.5 	3.5
Risk discount rate (%)
Health and Vitality1 	14.125 	11.875
Life and Invest1 	15.125 	13.125
VitalityHealth 	2.89 	3.61
VitalityLife 	3.065 	4.725
Rand/GB Pound exchange rate
Closing 	21.44 	17.98
Average 	19.75 	18.32
Margin over Expense inflation to derive Medical inflation (%)
South Africa 	3.00 	3.00
Expense inflation (%)2
South Africa 	– Health and Vitality 	7.39 	6.13
– Life and Invest 	8.33 	7.24
United Kingdom 	2.50 	2.50
Pre-tax investment return (%)
South Africa 	– Cash1 	11.00 	9.00
– Life and Invest bonds3 	12.50 	10.50
– Health and Vitality bonds3 	11.50 	9.25
– Equity1 	16.00 	14.00
United Kingdom – VitalityHealth risk-free rate 	0.27 	0.99
– VitalityLife risk–free rate 	0.44 	2.10
– VitalityLife IFRS interest rate 	1.35 	2.50
– VitalityLife investment return 	1.58 	2.50
Income tax rate (%)
South Africa 	28 	28
United Kingdom – long term 	19 	17
VitalityHealth Assumptions
– Margin (net of tax and cost of capital) (%) 	14.1 	14.1
– Annuity Factor 	6.37 	6.13
Projection term
– Health and Vitality 	20 years 	20 years
– Discovery Life – ViF 	40 years 	40 years
– Group Life 	10 years 	10 years
– VitalityLife 	No cap 	No cap
– VitalityHealth4 	20 years 	20 years
1 Derived as a margin over (or below for cash) the respective pre–tax investment return for bonds.
2 The inflation assumption is derived as the difference between the nominal and real yield curve at each duration. As an indication, the cash flow
weighted average inflation is shown in the table. For the United Kingdom, the expense inflation assumption is 1.50% in the first year.
3 As indications, the cash flow weighted averages derived from the relevant yield curve(s) are shown.
4 The VitalityHealth projection term of 20 years is used in the derivation of the Annuity Factor.

-- 49 of 56 --

48 Discovery Audited results for the year ended 30 June 2020
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2020
The Discovery Limited embedded value is calculated based on a risk discount rate using the CAPM approach with specific reference
to the Discovery beta coefficient. The assumed beta is fixed at 0.75. This has been set such that the risk discount rate proxies the
result of a Weighted Average Cost of Capital approach with reference to the capital structure of the Group and the observed beta
calculated using daily returns over a long time period. The observed beta is calculated with reference to the ALSI. The assumed beta
will only change if the capital structure of the Group and / or the observed beta calculated using daily returns over a long time period
suggest the beta assumption should depart significantly from the assumption at the financial year end. As beta values reflect the
historic performance of share prices relative to the market they may not allow fully for non–market related and non–financial risk.
Investors may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly.
Life and Invest mortality, morbidity and lapse and surrender assumptions were derived from internal experience, where available,
augmented by reinsurance and industry information.
The Health and Vitality lapse assumptions were derived from the results of recent experience investigations.
The VitalityHealth assumptions were derived from internal experience.
VitalityLife assumptions were derived from internal experience, where available, augmented by reinsurance, industry and Discovery
Limited group information.
Renewal expense assumptions were based on the results of the latest expense and budget information.
The initial expenses included in the calculation of the embedded value of new business are the actual costs incurred excluding
expenses of an exceptional or non–recurring nature.
From 30 June 2020, the yield curve underlying the embedded value calculations were changed from the Prudential Authority yield
curves to the Johannesburg Stock Exchange (“JSE”) yield curves. The South African investment return assumptions for Life, Invest,
Health and Vitality were based on the publicly available JSE risk–free nominal yield curve. The real yield assumption was set based
on the publicly available JSE risk–free real yield curve, adjusted to remove volatility due to the nature of the index linked government
bond market. Other economic assumptions were set relative to these two yield curves.
The current and projected tax position of the policyholder funds within the Life company has been taken into account in determining
the net investment return assumption.
The risk–free rate assumption for VitalityHealth was based on the single interest rate derived from the risk–free zero coupon sterling
yield curve.

-- 50 of 56 --

49
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2020
From 30 June 2018, VitalityHealth calculate the value in–force at the valuation date as the in–force written premium multiplied by
the Margin multiplied by the Annuity Factor, as set out in the table above. The Annuity Factor assumption is derived from assumed
future lapse rates and premium increases. The Margin assumption reflects profit margins after tax and Cost of Capital. The
assumptions underlying the Annuity Factor and Margin are set taking into account the current experience in the business at
different durations.
From 30 June 2020, VitalityLife bases the risk–free rate on UK swap rates. The inflation rate is set in line with the short–term
expectation of inflation for the first year, and beyond that is consistent with the Bank of England inflation target.
The cost of required capital is calculated using the difference between the risk discount rate and the net of tax asset return on
tangible assets. The VitalityLife Limited and the VitalityLife business on the Prudential licence required capital amount is assumed
to earn the investment return assumption, which is set based on the return on a portfolio of government and corporate bonds
assumed to back the required capital. The Life and Invest cost of required capital is calculated assuming shareholder cash flow is
limited to the cash flow available after having met both the required capital amount and an internally defined liquidity target capital
requirement of tangible assets.
The embedded value has been calculated in accordance with the Actuarial Society of South Africa’s Advisory Practice Note (“APN”)
107: Embedded Value Reporting, except the recommended disclosure of Free Surplus and Required Capital has been adjusted to
take into account the nature of the capital requirements in the covered businesses, as can be seen in Table 1 note 2.

-- 51 of 56 --

50 Discovery Audited results for the year ended 30 June 2020
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2020
Sensitivity to the embedded value assumptions
The risk discount rate uses the CAPM approach with specific reference to the Discovery beta coefficient. As beta values reflect the
historic performance of share prices relative to the market they may not allow fully for non–market related and non–financial risk.
Investors may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly.
The sensitivity of the embedded value and the embedded value of new business at 30 June 2020 to changes in the risk discount rate
is included in the tables below.
For each sensitivity illustrated below, all other assumptions have been left unchanged. No allowance has been made for
management action such as risk premium increases where future experience is worse than the base assumptions.
TABLE 9: EMBEDDED VALUE SENSITIVITY
Health and Vitality
R million
Adjusted
net worth2
Value
of
in-force
Cost of
required
capital
Base 	12 473 	22 321 	(419)
Impact of:
Risk discount rate +1% 	12 473 	21 039 	(451)
Risk discount rate -1% 	12 473 	23 740 	(382)
Lapses -10% 	12 080 	23 115 	(441)
Interest rates -1%1 	10 848 	22 250 	(403)
Equity and property market value -10% 	12 435 	22 321 	(419)
Equity and property return +1% 	12 473 	22 321 	(419)
Renewal expenses -10% 	12 556 	24 416 	(388)
Mortality and morbidity -5% 	12 674 	22 321 	(419)
Projection term +1 year 	12 473 	22 644 	(422)
1 All economic assumptions were reduced by 1%.
2 The sensitivity impact on the VitalityLife net of tax change in negative reserves is included in the adjusted net worth column.
The following table shows the effect of using different assumptions on the embedded value of new business.
TABLE 10: VALUE OF NEW BUSINESS SENSITIVITY
Health and Vitality
R million
Value of
new
business
Cost of
required
capital
Base 	910 	(27)
Impact of:
Risk discount rate +1% 	836 	(30)
Risk discount rate -1% 	993 	(25)
Lapses -10% 	969 	(29)
Interest rates -1%1 	918 	(26)
Equity and property return +1% 	910 	(27)
Renewal expense -10% 	1 032 	(26)
Mortality and morbidity -5% 	910 	(27)
Projection term +1 year 	928 	(28)
Acquisition costs -10% 	939 	(27)
1 All economic assumptions were reduced by 1%.

-- 52 of 56 --

51
Life and Invest 	VitalityHealth 	VitalityLife
Embedded
value
%
change
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
23 752 	(1 244) 	10 077 	(495) 	8 155 	(3 786) 	70 834
21 552 	(1 165) 	9 544 	(470) 	7 516 	(5 327) 	64 711 	(9)
26 342 	(1 336) 	10 667 	(524) 	8 850 	(1 904) 	77 926 	10
25 143 	(1 321) 	11 402 	(560) 	8 782 	(4 260) 	73 940 	4
24 290 	(1 229) 	10 560 	(524) 	8 356 	(4 530) 	69 618 	(2)
23 845 	(1 263) 	10 076 	(495) 	8 155 	(3 786) 	70 869 	0
24 031 	(1 250) 	10 088 	(495) 	8 155 	(3 786) 	71 118 	0
24 247 	(1 220) 	10 826 	(495) 	8 297 	(3 754) 	74 485 	5
25 312 	(1 123) 	11 625 	(495) 	8 354 	(3 742) 	74 507 	5
23 890 	(1 255) 	10 153 	(499) 	8 155 	(3 786) 	71 353 	1
Life and Invest 	VitalityHealth 	VitalityLife
Value of
new
business
%
change
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
668 	(82) 	262 	(56) 	353 	(106) 	1 922
453 	(77) 	186 	(52) 	220 	(137) 	1 399 	(27)
921 	(88) 	346 	(60) 	504 	(55) 	2 536 	32
888 	(87) 	396 	(63) 	525 	(146) 	2 453 	28
699 	(81) 	335 	(60) 	383 	(106) 	2 062 	7
692 	(82) 	263 	(56) 	353 	(106) 	1 947 	1
708 	(80) 	340 	(56) 	380 	(100) 	2 198 	14
764 	(74) 	422 	(56) 	398 	(96) 	2 241 	17
682 	(83) 	272 	(57) 	353 	(106) 	1 961 	2
820 	(82) 	298 	(56) 	483 	(106) 	2 269 	18
EMBEDDED VALUE STATEMENT continued
for the year ended 30 June 2020

-- 53 of 56 --

52 Discovery Audited results for the year ended 30 June 2020

-- 54 of 56 --

Transfer secretaries Computershare Investor Services Pty Limited
(Registration number: 2004/003647/07)
Rosebank Towers, 15 Biermann Avenue, Rosebank 2196
Private Bag X9000, Saxonwold, 2132
Sponsors Rand Merchant Bank (A division of FirstRand Bank Limited)
Secretary and registered office MJ Botha, Discovery Limited
(Incorporated in the Republic of South Africa)
(Registration number: 1999/007789/06)
Company tax reference number: 9652/003/71/7
JSE share code: 	DSY ISIN: ZAE000022331
JSE share code: 	DSBP ISIN: ZAE000158564
JSE bond code: 	DSYI
1 Discovery Place, Sandton 2146 PO Box 786722, Sandton 2146
Tel: (011) 529 2888 Fax: (011) 539 8003
Directors ME Tucker (UK) (Chairperson), A Gore* (Group Chief Executive Officer), HL Bosman, Dr BA Brink, SE de Bruyn, R Farber,
HD Kallner*, F Khanyile, NS Koopowitz*, D Macready1, Dr TV Maphai, HP Mayers2, Dr A Ntsaluba*, AL Owen (UK)3
, A Pollard*,
B Swartzberg*, DM Viljoen* (Financial Director), SV Zilwa
* Executive.
1 Appointed effective 3 February 2020.
2 Redesignated as a non-executive director effective 28 November 2019.
3 Retired effective 14 February 2020.
Annual financial results
– supervised by DM Viljoen CA(SA)
Embedded value statement
– prepared by M Curtis FASSA, FIA and P Bolink FASSA
– supervised by A Rayner FASSA, FIA

-- 55 of 56 --

Discovery
+27 11 529 2888 | askthecfo@discovery.co.za | www.discovery.co.za
Subsidiaries of Discovery Limited are authorised financial services providers.

-- 56 of 56 --